 Pyrido (2,3-B) pyrazine derivatives
专利摘要:
The present invention relates to compounds of the general formula (I) and pharmaceutically acceptable salts thereof useful as medicaments: In the above formula, R 1 is pyridyl (lower) alkyl, N-oxidodopyridyl (lower) alkyl or imidazolyl (lower) alkyl, R 2 is aminophenyl, [protected amino] phenyl, [[[halophenyl] (lower) alkenoyl] amino] phenyl, [[pyridyl (lower) alkenoyl] amino] phenyl, [[[N-oxaido Pyridyl] (lower) alkenoyl] amino] phenyl, [[[protected aminopyridyl] (lower) alkenoyl] amino] phenyl, [thiazolylcarbonylamino] phenyl which may have pyridyl, lower alkoxy and Naphthyl with halogen, [dihalophenyl] (lower) alkenyl, [N-oxidodopyridyl] (lower) alkenyl, [aminopyridyl] (lower) alkenyl, [protected aminopyridyl] ( Lower) alkenyl, [carboxypyridyl] (lower) alkenyl, [protected carboxypyridyl] (lower) alkenyl, [[pyridyl (lower) alkenyl] pyridyl] (lower) alkenyl, [[ Carboxy (lower) alkenyl] pyridyl] (lower) alkenyl, [[protected carboxy (lower) alkenyl] pyridyl] (lower) alkenyl, [pyridyl (lower) alkenyl] pyridyl, lower alkyl Benzothiazolyl or [halopyridylcarbonyl] amino, Provided that when R 2 is [[4-pyridyl (lower) alkenoyl] amino] phenyl, aminophenyl, [lower alkanoylamino] phenyl or [dihalophenyl] (lower) alkenyl, then R 1 is N- Oxidopyridyl (lower) alkyl or imidazolyl (lower) alkyl. 公开号:KR19990072053A 申请号:KR1019980704348 申请日:1996-12-13 公开日:1999-09-27 发明作者:노리히코 시마자키；아키히코 사와다；신야 와타나베 申请人:후지야마 아키라；후지사와 야꾸힝 고교 가부시키가이샤； IPC主号:
专利说明:
Pyrido (2,3-Ｂ) pyrazine derivatives The present invention relates to novel heterobicyclic derivatives. One object of the present invention is a novel and useful pyridopyrazine derivative having a potent phosphodiesterase IV (PDE IV) -inhibitory activity and a pharmaceutically acceptable activity that strongly inhibits the production of tumor necrosis factor (TNF). To provide a salt. Another object of the present invention is to provide a method for preparing pyridopyrazine derivatives and salts thereof. It is another object of the present invention to provide a pharmaceutical composition containing the pyridopyrazine derivative or a pharmaceutically acceptable salt thereof. Still another object of the present invention is pyridopyrazine as a medicament for the prevention and treatment of PDE-IV and TNF-included diseases such as chronic inflammatory diseases, special autoimmune diseases, sepsis-induced organ damage, etc. in humans and animals. It is to provide the use of a derivative or a pharmaceutically acceptable salt thereof. The desired pyridopyrazine derivatives of the invention can be represented by the following general formula (I): In the above formula, R 1 is pyridyl (lower) alkyl, N-oxidodopyridyl (lower) alkyl or imidazolyl (lower) alkyl, R 2 is aminophenyl, [rotected amino] phenyl, [[[halophenyl] (lower) alkenoyl] amino] phenyl, [[yridyl (lower) alkenoyl] amino] phenyl, [[[N-oxaido Pyridyl] (lower) alkenoyl] amino] phenyl, [[[rotected aminopyridyl] (lower) alkenoyl] amino] phenyl, [thiazolylcarbonylamino] phenyl which may have pyridyl, lower alkoxy and Naphthyl with halogen, [dihalophenyl] (lower) alkenyl, [N-oxidodopyridyl] (lower) alkenyl, [aminopyridyl] (lower) alkenyl, [rotected aminopyridyl] ( Lower) alkenyl, [carboxypyridyl] (lower) alkenyl, [rotected carboxypyridyl] (lower) alkenyl, [[yridyl (lower) alkenyl] pyridyl] (lower) alkenyl, [[ Carboxy (lower) alkenyl] pyridyl] (lower) alkenyl, [[rotected carboxy (lower) alkenyl] pyridyl] (lower) alkenyl, [yridyl (lower) alkenyl] pyridyl, lower alkyl Benzothiazolyl or [halopyridylcarbonyl] amino, Provided that when R 2 is [[4-pyridyl (lower) alkenoyl] amino] phenyl, aminophenyl, [lower alkanoylamino] phenyl or [dihalophenyl] (lower) alkenyl, then R 1 is N- Oxidopyridyl (lower) alkyl or imidazolyl (lower) alkyl. The objective compound (I) of the present invention can be produced by the following method. Method (1) Method (2) Method (3) Method (4) Method (5) In the above, R 1 and R 2 are each as defined above, R 2 a is [aminopyridyl] (lower) alkenyl, R 2 b is [acylaminopyridyl] (lower) alkenyl, R 2 c is [lower alkanoylamino] phenyl, [[[halophenyl] (lower) alkenoyl] amino] phenyl, [[yridyl (lower) alkenoyl] amino] phenyl, [[[N-oxidodopyri Dill] (lower) alkenoyl] amino] phenyl, [[[rotected aminopyridyl] (lower) alkenoyl] amino] phenyl, [thiazolylcarbonylamino] phenyl or acylaminopyriline which may have pyridyl Dill] (lower) alkenyl, R 2 d is aminophenyl or [aminopyridyl] (lower) alkenyl, R 2 e is aminophenyl, R 2 f is [lower alkanoylamino] phenyl, [[[halophenyl] (lower) alkenoyl] amino] phenyl, [[yridyl (lower) alkenoyl] amino] phenyl, [[[N-oxidodopyri Dill] (lower) alkenoyl] amino] phenyl, [[[rotected aminopyridyl] (lower) alkenoyl] amino] phenyl or [thiazolylcarbonylamino] phenyl, which may have pyridyl, R 3 is lower alkanoyl, [halophenyl] (lower) alkenoyl, pyridyl (lower) alkenoyl, [N-oxidodopyridyl] (lower) alkenoyl, [rotected aminopyridyl] (lower) alkenes Thiazolylcarbonyl, which may have noyl or pyridyl, R 4 is an N-protecting group, Y is halogen, Y - is a halide, A is lower alkylene. Starting compound (II) of the present invention can be prepared by the following method. Method (A) Method (B) Method (C) Method (D) Method (E) Method (F) Method (G) Method (H) Method (I) Method (J) Method (K) Method (L) In the above, R 2 , R 2 e , R 2 f and R 3 are each as defined above, R 5 is lower alkyl, R 6 is protected aminophenyl, R 7 is aminophenyl, R 8 is dihalophenyl, N-oxidodopyridyl, aminopyridyl, protected aminopyridyl, carboxypyridyl, protected carboxypyridyl, [yridyl (lower) alkenyl] pyridyl, [carboxy (lower) ) Alkenyl] pyridyl or [rotected carboxy (lower) alkenyl] pyridyl, R 9 is halo (lower) alkyl, X 1 , X 2 , X 3 , X 4 and X 5 are each an exit group, Q is lower alkenylene. Suitable pharmaceutically acceptable salts of the desired compound (I) are conventional non-toxic salts, including salts with inorganic bases, for example alkali metal salts (e.g. sodium salts, potassium salts, etc.) and alkaline earth metal salts ( Such as calcium salts, magnesium salts, etc.) or ammonium salts; Salts with organic base salts, for example organic amine salts such as triethylamine salts, pyridine salts, picoline salts, ethanolamine salts, triethanolamine salts, dicyclohexylamine salts, N, N'-dibenzylethylenediamine Salts, etc.); Inorganic acid addition salts such as hydrochloride, hydrobromide, sulfate, phosphate, etc .; Organic carboxylic acid or sulfonic acid addition salts (e.g. formate, acetate, trifluoroacetate, maleate, tartrate, fumarate, methanesulfonate, benzenesulfonate, toluenesulfonate, etc.), basic or acidic amino acids (e.g. Base or acid addition salts such as salts with arginine, aspartic acid, glutamic acid, and the like. In the foregoing and the following description of the specification, suitable examples and embodiments of various definitions falling within the scope of the present invention are described in detail below. The term "lower" means unless otherwise indicated, having 1 to 6 carbon atoms, preferably 1 to 4 carbon atoms. The term "advanced" means 7 to 20 carbon atoms unless otherwise indicated. Suitable "lower alkyl" and terms "pyridyl (lower) alkyl", "N-oxidodopyridyl (lower) alkyl", "imidazolyl (lower) alkyl", "lower alkylbenzotriazolyl" and "halo ( "Lower alkyl moiety" in "lower) alkyl" includes one to six carbon atom (s) such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, secondary butyl, t-butyl, pentyl, t-pentyl, hexyl, etc. Linear or branched groups with) may be included, more preferred examples are C 1 -C 4 alkyl, most preferred may be methyl. Suitable "lower alkenyl" and terms "[dihalophenyl] (lower) alkenyl", "[N-oxidodopyridyl] (lower) alkenyl", "[aminopyridyl] (lower) alkenyl", "[Protected [aminopyridyl] (lower) alkenyl", "[carboxypyridyl] (lower) alkenyl", "[rotected carboxypyridyl] (lower) alkenyl", "[[yridyl] (Lower) alkenyl] pyridyl] (lower) alkenyl "," [[carboxy] (lower) alkenyl] pyridyl] (lower) alkenyl "," [[rotected carboxy] (lower) alkenyl] In the "pyridyl] (lower) alkenyl" and "[yridyl] (lower) alkenyl] pyridyl""lower alkenyl moieties" are vinyl, 1- (or 2-) propenyl, 1- (or 2 Or 3-) butenyl, 1- (or 2- or 3- or 4-) pentenyl, 1- (or 2- or 3- or 4- or 5-) hexenyl, methylvinyl, ethylvinyl, 1 -(Or 2- or 3-) methyl-1- (or 2-) propenyl, 1- (or 2- or 3-) ethyl-1- (or 2-) propenyl, 1- (or 2-or 3- or 4-) methyl-1- (or 2- or 3-) butenyl and the like, Preferred examples Wook (C 2 -C 4) alkenyl can be imidazol, can be the most preferable example is vinyl. Suitable "lower alkynyl" include ethynyl, 1-propynyl, propargyl, 1-methylpropargyl, 1 or 2 or 3-butynyl, 1 or 2 or 3 or 4-pentynyl, 1 or 2 or 3 or 4 or 5-hexynyl and the like. Suitable "lower alkoxy" may include methoxy, ethoxy, propoxy, isopropoxy, butoxy, t-butoxy, pentyloxy, t-pentyloxy, hexyloxy and the like. Suitable "lower alkylenes" may include straight or branched chain groups such as methylene, ethylene, trimethylene, tetramethylene, pentamethylene, hexamethylene, methylmethylene, ethylethylene, propylene and the like, more preferred examples being C 1 -C 4 may be alkylene and the most preferred example may be methylene. Suitable "lower alkenylenes" include vinylene, propenylene, 1- (or 2-) butenylene, 1- (or 2- or 3-) pentenylene, 1- (or 2- or 3-) hexenyl Ethylene, methylvinylene, ethylvinylene, 1- (or 2- or 3-) methylpropenylene, 1- (or 2- or 3-) ethylpropenylene, 1- (or 2- or 3- or 4-) methyl-1- (or 2-) butenylene and the like. Suitable "cyclo (lower) alkyl" may include cyclopentyl, cyclohexyl and the like. Suitable "cyclo (lower) alkenyls" may include cyclophenhexenyl, cyclohexadienyl, and the like. Suitable "aryls" can include phenyl, naphthyl and the like. Suitable "halogens" and the terms "halo (lower) alkyl", "[[[halophenyl] (lower) alkenoyl] amino] phenyl", "[dihalophenyl] (lower) alkenyl" and "[halopyridyl "Halogen part" in "carbonyl] amino" may include fluorine, chlorine, bromine and iodine. Suitable "leaving groups" can include acid residues, loweralkoxy exemplified above, and the like. Suitable “acid residues” may include halogens, acyloxy, and the like exemplified above. Suitable "halides" can include fluoride, bromide, chloride, and the like. "Protected carboxy moiety" in suitable "protected carboxy" and the terms "[rotected carboxypyridyl] (lower) alkenyl" and "[[rotected carboxy (lower) alkenyl] pyridyl (lower) alkenyl" As esterified carboxy may be included. Suitable examples of such esters include lower alkyl esters (eg, methyl esters, ethyl esters, propyl esters, isopropyl esters, butyl esters, isobutyl esters, t-butyl esters, pentyl esters, t-pentyl esters, hexyl esters, etc.); Lower alkenyl esters such as vinyl esters, allyl esters, etc .; Lower alkynyl esters (eg, ethynyl esters, propynyl esters, etc.); Lower alkoxy (lower) alkyl esters (eg, methoxymethyl ester, ethoxymethyl ester, isopropoxymethyl ester, 1-methoxyethyl ester, 1-ethoxyethyl ester, etc.); Lower alkylthio (lower) alkyl esters such as methylthiomethyl ester, ethylthiomethyl ester, ethylthioethyl ester, isopropoxythiomethyl ester and the like; Mono (or di or tri) halo (lower) alkyl esters (eg 2-iodoethyl ester, 2,2,2-trichloroethyl ester, etc.); Lower alkanoyloxy (lower) alkyl esters (e.g. acetoxymethyl ester, propionyloxymethyl ester, butyryloxymethyl ester, valeryloxymethyl ester, pivaloyloxymethyl ester, hexanoyloxymethyl ester, 1- Acetoxyethyl ester, 2-acetoxyethyl ester, 2-propionyloxyethyl ester, etc.); Lower alkoxycarbonyloxy (lower) alkyl esters (e.g. methoxycarbonyloxymethyl ester, ethoxycarbonyloxymethyl ester, propoxycarbonyloxymethyl ester, 1- (or 2-)-[methoxycarbonyl Oxy] ethyl ester, 1- (or 2-)-[ethoxycarbonyloxy] ethyl ester, 1- (or 2-)-[ropoxycarbonyloxy] ethyl ester, 1- (or 2-)-[ Isopropoxycarbonyloxy] ethyl ester, etc.); Lower alkanesulfonyl (lower) alkyl esters (eg mesylmethyl ester, 2-mesylethyl ester, etc.); Lower alkoxycarbonyloxy (lower) alkyl esters (e.g. methoxycarbonyloxymethyl ester, ethoxycarbonyloxymethyl ester, propoxycarbonyloxymethyl ester, t-butoxycarbonyloxymethyl ester, 1- ( Or 2-) methoxycarbonyloxyethyl ester, 1- (or 2-) ethoxycarbonyloxyethyl ester, 1- (or 2-)-isopropoxycarbonyloxyethyl ester and the like); Phthalidylidene (lower) alkyl esters; (5-lower alkyl-2-oxo-1,3-dioxol-4-yl) (lower) alkylester [e.g. (5-methyl-2-oxo-1,3-dioxol-4-yl) methyl Esters, (5-ethyl-2-oxo-1,3-dioxol-4-yl) methyl ester, (5-propyl-2-oxo-1,3-dioxol-4-yl) ethyl ester and the like]; Mono (or di or tri) alkyl (lower) alkyl esters, for example mono (or di or tri) phenyl (lower) alkyl esters, which may have one or more substituent (s) (eg benzyl ester, 4- Methoxybenzyl ester, 4-nitrobenzyl ester, phenethyl ester, trityl ester, benzhydryl ester, bis (methoxyphenyl) methyl ester, 3,4-dimethoxybenzyl ester, 4-hydroxy-3,5 -Di-t-butylbenzyl ester and the like); Aryl esters that may have one or more suitable substituent (s), such as substituted or unsubstituted phenyl esters, such as phenyl esters, tolyl esters, t-butylphenyl esters, xylyl esters, mesityl esters, cumenyl esters , 4-chlorophenyl ester, 4-methoxyphenyl ester and the like); Tri (lower) alkylsilyl esters; Lower alkylthioesters (eg, methylthioesters, ethylthioesters, etc.) and the like, and more suitable examples may be C 1 -C 4 alkoxycarbonyl, most preferred example may be methoxycarbonyl. Suitable "hydroxy protecting groups" in the term "protected hydroxy" include acyl, mono (or di or tri) phenyl (lower) alkyl (eg benzyl, 4) which may have one or more suitable substituent (s). -Methoxybenzyl, trityl and the like), trisubstituted silyls (e.g. tri (lower) alkylsilyl (e.g. trimethylsilyl, t-butyldimethylsilyl, etc.), etc.), tetrahydropyranyl and the like. Suitable "N-protecting groups" include acyl, or mono (or di or tri) aryl (lower) alkyl, such as mono (or di or tri) phenyl (lower) alkyl (e.g. benzyl, trityl, etc.) and the like. Such conventional protection groups and the like. Suitable "protected amino" and the terms "[rotected amino] phenyl", "[[[rotected aminopyridyl] (lower) alkenoyl] amino] phenyl" and "[rotected aminopyridyl] (lower) al "Protected amino moiety" in "kenyl" is acylamino, or mono (or di or tri) aryl (lower) alkyl, for example mono (or di or tri) phenyl (lower) alkyl (e.g. benzyl, tri Amino groups substituted by conventional protecting groups such as yl). Suitable "acyl" and "acyl moieties" in the terms "acylamino" and "acyloxy" include acyl groups, including aromatic acyl and carbamoyl, thiocarbamoyl, aliphatic acyl groups and aromatic rings or heterocyclic rings, respectively. Referred to as heterocyclic acyl). Suitable examples of such acyl are Carbamoyl; Thiocarbamoyl; Lower or higher alkanoyls such as formyl, acetyl, propanoyl, butanoyl, 2-methylpropanoyl, pentanoyl, 2,2-dimethylpropanoyl, hexanoyl, heptanoyl, octanoyl, nonano Day, decanoyl, undecanoyl, dodecanoyl, tridecanoyl, tetradecanoyl, pentadecanoyl, hexadecanoyl, heptadecanoyl, octadecanoyl, nonadecanoyl, aicosanoyl, etc.); Lower or higher alkenoyl such as acryloyl, 2- (or 3-)-butenoyl, 2- (or 3- or 4-)-pentenoyl, 2- (or 3- or 4- or 5-) -Hexenoyl, etc.); Lower or higher alkoxycarbonyl (eg, methoxycarbonyl, ethoxycarbonyl, isopropoxycarbonyl, t-butoxycarbonyl, t-pentyloxycarbonyl, heptyloxycarbonyl, etc.); Lower or higher alkylsulfonyl (eg methylsulfonyl, ethylsulfonyl, etc.); Lower or higher alkoxysulfonyl (eg methoxysulfonyl, ethoxysulfonyl, etc.); Lower alkadienoyl (eg, heptadienoyl, hexadienoyl, etc.); Cyclo (lower) alkylcarbonyl (eg cyclopropylcarbonyl, cyclopentylcarbonyl, cyclohexylcarbonyl, etc.); Cyclo (lower) alkylidene (lower) alkanoyl (eg, cycloheptylideneacetyl, cycloheptylidenepropanoyl, cyclohepsylideneacetyl, cyclohepsylidenepropanoyl, etc.); Cyclo (lower) alkyloxycarbonyl (eg cyclopentyloxycarbonyl, cyclohexyloxycarbonyl, etc.); Lower alkylglyoxyloyl (eg, methylglyoxyloyl, ethylglyoxyloyl, propylglyoxyloyl, etc.); Aliphatic acyl such as lower alkoxyglyoxyloyl (eg, methoxyglyoxyloyl, ethoxyglyoxyloyl, propoxyglyoxyloyl, etc.); Aroyl (eg benzoyl, toluoyl, naphthoyl, etc.); Ar (lower) alkanoyl) [e.g. phenyl (lower) alkanoyl (e.g. phenylacetyl, phenylpropanoyl, phenylbutanoyl, phenylisobutanoyl, phenylpentanoyl, phenylhexanoyl, etc.), naphthyl (lower) Alkanoyl (eg, naphthylacetyl, naphthylpropanoyl, naphthylbutanoyl, etc.); Ar (lower) alkenoyl) [e.g. Phenyl (lower) alkenoyl (e.g. phenylpropenyl, phenylbutenoyl, phenylmethacryloyl, phenylpentenoyl, phenylhexenoyl, etc.), naphthyl (lower) Alkenoyl (eg, naphthylpropenyl, naphthylbutenoyl, etc.); Ar (lower) alkoxycarbonyl (eg phenyl (lower) alkoxycarbonyl (eg benzyloxycarbonyl, etc.), etc.); Aryloxycarbonyl (eg, phenoxycarbonyl, naphthyloxycarbonyl, etc.); Aryloxy (lower) alkanoyl (eg, phenoxyacetyl, phenoxypropionyl, etc.); Arylglyoxyloyl (eg, phenylglyoxyloyl, naphthylglyoxyloyl, etc.); Arylsulfonyl (eg phenylsulfonyl, p-tolylsulfonyl, etc.); Ar (lower) alkylsulfonyl [e.g. Phenyl (lower) alkylsulfonyl (e.g. benzylsulfonyl, phenylethylsulfonyl, etc.), naphthyl (lower) alkylsulfonyl (e.g. naphthylmethylsulfonyl, naphthyl Ethyl sulfonyl, etc.); Heterocyclic carbonyl; Heterocyclic (lower) alkanoyl (eg, heterocyclic acetyl, heterocyclic propanoyl, heterocyclic butanoyl, heterocyclic pentanoyl, heterocyclic hexanoyl, etc.); Heterocyclic (lower) alkenoyl (eg, heterocyclic propenoyl, heterocyclic butenoyl, heterocyclicpentenoyl, heterocyclic hexenoyl, etc.); Heterocyclicglyoxyloyl; Heterocyclic acyls such as heterocyclicoxycarbonyl and the like can be mentioned, The above-mentioned terms "heterocyclic carbonyl", "heterocyclic (lower) alkanoyl", "heterocyclic (lower) alkenoyl", "heterocyclicoxycarbonyl" and "heterocyclic glyoxylo" Suitable “heterocyclic moieties” in one " means more particularly saturated or unsaturated monocyclic or polycyclic heterocyclic groups containing at least one heteroatom such as oxygen, sulfur, nitrogen and the like. Particularly preferred heterocyclic groups are also unsaturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic groups containing 1 to 4 nitrogen atom (s), for example pyrrolyl. , Pyrrolinyl, imidazolyl, pyrazolyl, pyridyl, dihydropyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazolyl (e.g., 1H-1,2,4-triazolyl, 4H-1 , 2,4-triazolyl, 1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl and the like), tetrazolyl (eg 1H-tetrazolyl, 2H-tetrazolyl, etc.); Saturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic groups containing 1 to 4 nitrogen atom (s), for example pyrrolidinyl, imidazolidinyl, piperi Dill, piperazinyl and the like; Unsaturated condensed heterocyclic groups containing 1 to 4 nitrogen atom (s), for example indolyl, isoindoleyl, indolinyl, indolinyl, benzimidazolyl, quinolyl, tetrahydroquinolyl ( Such as 1,2,3,4-tetrahydroquinolyl), isoquinolyl, indazolyl, benzotriazolyl, benzopyrimidinyl (e.g. benzo [b] pyrimidinyl, etc.); Unsaturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic groups containing 1 to 2 oxygen atom (s) and 1 to 3 nitrogen atom (s), eg oxa Zolyl, isoxazolyl, oxdiazolyl (eg, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,5-oxadiazolyl, etc.); Saturated 3- to 8-membered (more preferably 5- or 6-membered) heteromonocyclic groups containing 1 to 2 oxygen atom (s) and 1 to 3 nitrogen atom (s), eg Polyyl, cydnonyl and the like; Unsaturated condensed heterocyclic groups containing 1 to 2 oxygen atom (s) and 1 to 3 nitrogen atom (s) such as benzoxazolyl, benzoxadiazolyl and the like; Unsaturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic groups containing 1 to 2 sulfur atom (s) and 1 to 3 nitrogen atom (s), for example thiazolyl , Isothiazolyl, thiadiazolyl (e.g. 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,5-thiadiazolyl And the like), dihydrothiazinyl and the like; Saturated 3- to 8-membered (more preferably 5- or 6-membered) heteromonocyclic groups containing 1 to 2 sulfur atom (s) and 1 to 3 nitrogen atom (s), for example thiazoli Denyl and the like; Unsaturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic groups containing 1 to 2 sulfur atom (s), for example thienyl, dihydrodithiinyl, dihydrodithionyl Etc; Unsaturated condensed heterocyclic groups containing 1 to 2 sulfur atom (s) and 1 to 3 nitrogen atom (s) such as benzothiazolyl, benzothiadiazolyl and the like; Unsaturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic groups containing one oxygen such as furyl and the like; Unsaturated condensed heterocyclic groups containing 1 to 2 oxygen atom (s) such as benzodioxolyl (such as methylenedioxyphenyl), benzofuryl and the like; Unsaturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic groups containing one oxygen atom and 1 to 2 sulfur atom (s), such as dihydrooxatinyl, and the like; Unsaturated condensed heterocyclic groups containing 1 to 2 sulfur atom (s) such as benzothienyl (eg benzo [b] thienyl and the like), benzodithiyl and the like; It may be an unsaturated condensed heterocyclic group containing one oxygen atom and 1 to 2 sulfur atom (s), for example a heterocyclic group such as benzoxatinyl and the like. The above-mentioned acyl moiety includes lower alkyl exemplified above, lower alkoxy exemplified above, lower alkylthio as exemplified by lower alkyl moiety, cyclo (lower) alkyl exemplified above, cyclo (lower) alkenyl, exemplified above The (lower) alkyl moiety is cyclo (lower) alkyloxy as exemplified above, halogen exemplified above, amino exemplified protected amino, hydroxy, exemplified protected hydroxy, cyano, nitro, carboxy, The protected carboxy, sulfo, sulfamoyl, imino, oxo, lower alkyl moieties exemplified above are mono (lower) alkyl, carbamoyloxy, halogen moieties and lower alkyl moieties as exemplified above, respectively, as illustrated above. (Or di or tri) -halo (lower) alkyl, the lower alkyl moiety of which hydroxy (lower) alkyl as exemplified above, the heterocyclic group exemplified above, heterocyclic The minutes may have heterocyclicoxy, nitro as exemplified above and the heterocyclic moiety may have heterocyclic amino as exemplified above, suitable substituent (s) and the aryl moiety as exemplified above, The arylsulfonyl, aryl moiety and lower alkyl moiety, wherein the aryl moiety is illustrated above, respectively, are the ar (lower) alkyl, the protected carboxy moiety, and the lower alkenyl moiety, as illustrated above, respectively. The (lower) alkenyl, acyl exemplified above, acyl moiety may have from 1 to 10 identical or different suitable substituent (s), such as acylamino as exemplified above. Preferred acyl as defined above may be aliphatic acyl such as lower alkanoyl (eg acetyl etc.) and most preferred may be acetyl. Suitable "lower alkanoyl moieties" in the term "[lower alkanoylamino] phenyl" may be mentioned above. The terms "[[[halophenyl] (lower) alkenoyl] amino] phenyl", "[[yridyl (lower) alkenoyl] amino] phenyl", "[[[N-oxidodopyridyl] (lower) alkene Suitable "lower alkenoyl moieties" in "noyl] amino] phenyl" and "[[[rotected aminopyridyl] (lower) alkenoyl] amino] phenyl" may be mentioned. The preparation of the desired compound and starting compound is described in detail below. Method 1 Compound (I) or a salt thereof can be prepared by reacting compound (II) or a salt thereof with compound (III) or a salt thereof. The reaction generally does not adversely affect water, alcohols (e.g. methanol, ethanol, etc.), benzene, N, N-dimethylformamide, tetrahydrofuran, toluene, methylene chloride, ethylene chloride, chloroform, diethyl ether or the reaction. In the same solvent as other solvents. The reaction temperature is not critical and the reaction is generally carried out under warming to heating. Method 2 Compound (Ib) or a salt thereof can be prepared by carrying out an acylation reaction with respect to the compound (Ia) or a reactive derivative thereof in the amino group, or salt thereof. Suitable acylating agents used in the acylation reactions may include compounds of the general formula R 11 -OH (XXV), wherein R 11 is acyl, or reactive derivatives thereof, or salts thereof. Suitable reactive derivatives in the amino group of compound (Ia) include imino in the form of Schiff bases or tautomeric enamines thereof formed by reaction of compound (Ia) with carbonyl compounds such as aldehydes, ketones, and the like. Isomers of; Silyl derivatives formed by reaction of compound (Ia) with a silyl compound such as N, O-bis (trimethylsilyl) acetamide, N-trimethylsilylacetamide, and the like; Derivatives formed by the reaction of compound (Ia) with phosphorus trichloride or phosgene, and the like. Suitable reactive derivatives of compound (XXV) may include acid halides, acid anhydrides, activated esters, isocyanates and the like. Suitable examples of reactive derivatives include acid chlorides; Acid azide; Substituted phosphoric acid [e.g. dialkylphosphoric acid, phenylphosphoric acid, diphenylphosphoric acid, dibenzyl phosphoric acid, halogenated phosphoric acid, etc.], dialkyl phosphorous acid, sulfurous acid, thiosulfic acid, alkanesulfic acid [e.g. Mixed acid anhydrides with acids such as sulfuric acid, alkylcarboxylic acids, aliphatic carboxylic acids such as pivalic acid, pentanoic acid, isopentanoic acid, 2-ethylbutyric acid, trichloroacetic acid and the like; Aromatic carboxylic acids such as benzoic acid and the like; Symmetric acid anhydrides; Activated amides with imidazole, 4-substituted imidazole, dimethylpyrazole, triazole or tetrazole; Activated esters such as cyanomethyl ester, methoxymethyl ester, dimethyliminomethyl [(CH 3 ) 2 N + = CH-] ester, vinyl ester, propargyl ester, p-nitrophenyl ester, 2,4- Dinitrophenyl ester, trichlorophenyl ester, pentachlorophenyl ester, mesylphenyl ester, phenylazophenyl ester, phenylthio ester, p-nitrophenyl thioester, p-cresyl thioester, carboxymethyl thioester, pyranyl ester , Pyridyl ester, piperidyl ester, 8-quinolyl thioester and the like]; N-hydroxy compounds [e.g., N, N-dimethylhydroxylamine, 1-hydroxy-2- (1H) -pyridone, N-hydroxysuccinimide, N-hydroxybenzotriazole, N-hydroxy Oxyphthalimide, 1-hydroxy-6-chloro-1H-benzotriazole and the like]; Substituted or unsubstituted aryl isocyanate; Substituted or unsubstituted aryl isothiocyanates and the like can be mentioned. These reactive derivatives can be arbitrarily selected from these according to the kind of compound (XXV) used. The reaction is generally water, acetone, dioxane, acetonitrile, chloroform, methylene chloride, ethylene chloride, tetrahydrofuran, ethyl acetate, N, N-dimethylformamide, pyridine or other organic solvents that do not adversely affect the reaction. It is carried out in a conventional solvent such as. These conventional solvents can also be used in admixture with water. In this reaction, when the compound (XXV) is used in free acid form or in salt form thereof, the reaction is preferably N, N'-dicyclohexylcarbodiimide; N-cyclohexyl-N'-morpholinoethylcarbodiimide; N-dicyclohexylka-N '-(4-diethylaminocyclohexyl) carbodiimide; N, N'-diisopropylcarbodiimide; N-ethyl-N '-(3-dimethylaminopropyl) carbodiimide; N, N-carbonyl-bis (2-methylimidazole); Pentamethyleneketene-N-cyclohexylimine; Diphenylketene-N-cyclohexylimine; Ethoxyacetylene; 1-alkoxy-1-chloroethylene; Trialkyl phosphites; Isopropyl polyphosphate; Phosphorus oxychloride (phosphoryl chloride); Phosphorus trichloride; Thionyl chloride; Oxalyl chloride; Triphenylphosphite; 2-ethyl-7-hydroxybenzisoxazolium salt; 2-ethyl-5- (m-cellophenyl) isoxazolium hydroxide intramolecular salt; 1- (p-chlorobenzenesulfonyloxy) -6-chloro-1H-benzotriazole; It is carried out in the presence of a conventional condensing agent such as the so-called Vilsmeier reagent prepared by reacting N, N-dimethylformamide with thionyl chloride, phosgene, phosphorus oxychloride, and the like. The reaction may also be carried out in the presence of organic or inorganic bases such as alkali metal bicarbonates, tri (lower) alkylamines, pyridine, N- (lower) alkylmorpholines, N, N-di (lower) alkylbenzylamines and the like. The reaction temperature is not critical and the reaction is generally carried out under cooling or heating. Method 3 Compound (Id) or a salt thereof can be prepared by carrying out a deacylation reaction with respect to compound (Ic) or a salt thereof. Suitable methods of this deacylation reaction may include conventional methods such as hydrolysis, reduction, and the like. (i) hydrolysis: The hydrolysis reaction is preferably carried out in the presence of an acid comprising a base or Lewis acid. Suitable bases include alkali metals [e.g. sodium, potassium, etc.], alkaline earth metals [e.g. magnesium, calcium, etc.], hydroxides or carbonates or bicarbonates thereof, trialkylamines [e.g. trimethylamine, triethylamine, etc.], picoline, Inorganic bases and organic bases such as 1,5-diazabicyclo [4.3.0] non-5-ene and the like can be included. Suitable acids may include organic acids such as formic acid, acetic acid, propionic acid, trichloroacetic acid, trifluoroacetic acid and the like and inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, hydrogen chloride, hydrogen bromide and the like. Removal reactions with Lewis acids, such as trihaloacetic acid (eg trichloroacetic acid, trifluoroacetic acid, etc.) are preferably carried out in the presence of a cation trapping agent (eg anisole, phenol, etc.). do. The reaction is generally water, alcohol [e.g. methanol, ethanol, isopropyl alcohol, etc.], tetrahydrofuran, dioxane, toluene, methylene chloride, ethylene chloride, chloroform, N, N-dimethylformamide, N, N-dimethyl It is carried out in conventional solvents or mixtures thereof, such as acetamide or other solvents that do not adversely affect the reaction. The reaction temperature is not critical and the reaction is generally carried out under cooling or warming. (ii) reduction: Reduction is carried out in conventional manner, including chemical reduction and catalytic reduction. Suitable reducing agents used for chemical reduction are hydrides (eg hydrogen iodide, hydrogen sulfide, lithium aluminum hydride, sodium borohydride, sodium cyanoborohydride, etc.), or metals (eg tin, zinc, iron, etc.) or metallic compounds For example chromium chloride, chromium acetate and the like and an organic or inorganic acid such as formic acid, acetic acid, propionic acid, trifluoroacetic acid, p-toluenesulfonic acid, hydrochloric acid, hydrobromic acid and the like. Suitable catalysts used for catalytic reduction include platinum catalysts (e.g. platinum plates, sponge platinum, platinum black, colloidal platinum, platinum oxide, platinum wires, etc.), palladium catalysts (e.g. sponge palladium, palladium black, palladium oxide). , Palladium on carbon, colloidal palladium, palladium on barium sulfate, palladium on barium carbonate, etc.], nickel catalysts (e.g., reduced nickel, nickel oxide, Raney nickel, etc.), cobalt catalysts (e.g., reduced cobalt, Rani cobalt, etc.), Iron catalysts such as reduced iron, Raney iron, Ullman iron and the like. Reduction reactions generally involve water, alcohols (eg methanol, ethanol, isopropyl alcohol, etc.), tetrahydrofuran, dioxane, toluene, methylene chloride, ethylene chloride, chloroform, N, N-dimethylformamide, N, N- It is carried out in conventional solvents or mixtures thereof such as dimethylacetamide or other solvents that do not adversely affect the reaction. In addition, when the above-mentioned acids used for chemical reduction are liquids, they can also be used as solvents. The reaction temperature of this reduction reaction is not critical and the reaction is generally carried out under cooling or warming. Method 4 Compound (If) or a salt thereof can be prepared by reacting a reactive derivative thereof in the compound (Ie) or an amino group, or a salt thereof with a reactive derivative thereof in the compound (IV) or a carboxy group, or a salt thereof. This reaction can be carried out in a manner similar to Method 2 mentioned above, so the reagents used and the reaction conditions (eg solvent, reaction temperature, etc.) can also be referred to in the description in Method 2. Method 5-1 Compound (VII) or a salt thereof can be prepared by reacting compound (Va) or a salt thereof with compound (VI) or a salt thereof. The reaction is generally bad for water, alcohols (eg methanol, ethanol, etc.), benzene, N, N-dimethylformamide, tetrahydrofuran, toluene, methylene chloride, ethylene chloride, chloroform, dioxane, diethyl ether or reaction It is carried out in the same solvent or mixture thereof as other solvents which do not affect. The reaction temperature is not critical and the reaction is generally carried out under cooling or heating. The reaction is generally carried out in the presence of an acid comprising Lewis acid. Suitable acids include organic acids (e.g. formic acid, acetic acid, propionic acid, trichloroacetic acid, trifluoroacetic acid, etc.) and inorganic acids (e.g. hydrochloric acid, hydrobromic acid, sulfuric acid, hydrogen chloride, hydrogen bromide, zinc halide (e.g. zinc chloride, zinc bromide) Etc.) may be included. The reaction can also be carried out by alkali metals (e.g. sodium, potassium, etc.), alkali metal hydroxides (e.g. sodium hydroxide, potassium hydroxide, etc.), alkali metal bicarbonates (e.g. sodium bicarbonate, potassium bicarbonate, etc.), alkali metal carbonates (e.g. sodium carbonate, Potassium carbonate), tri (lower) alkylamines (e.g. trimethylamine, triethylamine, diisopropylethylamine, etc.), alkali metal hydrides (e.g. sodium hydride), alkali metal (lower) alkoxides (e.g. Sodium methoxide, sodium ethoxide, etc.), pyridine, lutidine, picoline, dimethylaminopyridine, N- (lower) alkylmorpholine, N, N-di (lower) alkylbenzylamine, N, N-di (lower) It may be carried out in the presence of an inorganic or organic base such as alkylaniline and the like. If the bases, acids and / or starting compounds are liquids they may also be used as solvents. Method 5-2 Compound (Ig) or a salt thereof can be prepared by carrying out the elimination reaction of the N-protecting group with respect to the compound (VII) or a salt thereof. This reaction can be carried out in a similar manner to Method 3 mentioned above, so the reagents used and the reaction conditions (eg solvent, reaction temperature, etc.) can also be referred to in the description of Method 3. Method (A) Compound (X) or a salt thereof can be prepared by reacting compound (VIII) or a salt thereof with compound (IX) or a salt thereof. The reaction generally does not adversely affect water, alcohols (eg methanol, ethanol, etc.), benzene, N, N-dimethylformamide, tetrahydrofuran, toluene, methylene chloride, ethylene chloride, chloroform, diethyl ether or the reaction. Is performed in the same solvent as other solvents. The reaction temperature is not critical and the reaction is generally carried out under warming to heating. If the starting compound is a liquid it can also be used as a solvent. Method (B) Compound (II) or a salt thereof can be prepared by carrying out a reduction reaction with respect to compound (X) or a salt thereof. Reduction is carried out in conventional manner, including chemical reduction and catalytic reduction. Suitable reducing agents used for chemical reduction are hydrides (eg hydrogen iodide, hydrogen sulfide, lithium aluminum hydride, sodium borohydride, sodium cyanoborohydride, etc.), or metals (eg tin, zinc, iron, etc.) or metallic compounds For example chromium chloride, chromium acetate and the like and an organic or inorganic acid such as formic acid, acetic acid, propionic acid, trifluoroacetic acid, p-toluenesulfonic acid, hydrochloric acid, hydrobromic acid and the like. Suitable catalysts used for catalytic reduction include platinum catalysts (e.g. platinum plates, sponge platinum, platinum black, colloidal platinum, platinum oxide, platinum wires, etc.), palladium catalysts (e.g. sponge palladium, palladium black, palladium oxide). , Palladium on carbon, colloidal palladium, palladium on barium sulfate, palladium on barium carbonate, etc.], nickel catalysts (e.g., reduced nickel, nickel oxide, Raney nickel, etc.), cobalt catalysts (e.g., reduced cobalt, Rani cobalt, etc.), Conventional catalysts such as iron catalysts (eg, reduced iron, Raney iron, etc.), copper catalysts (eg, reduced copper, Rani copper, Woolman copper, etc.). Reduction reactions are generally carried out in conventional solvents or mixtures thereof which do not adversely affect the reaction, such as water, alcohols (e.g. methanol, ethanol, propanol, etc.), tetrahydrofuran, dioxane or N, N-dimethylformamide. Perform. The reaction temperature is not critical and the reaction is generally carried out under cooling or warming. Method C Compound (XI) or a salt thereof can be prepared by reacting compound (II) or a salt thereof with compound (XXIV) or a salt thereof. This reaction can be carried out in a manner similar to Method 1 mentioned above, so the reagents used and the reaction conditions (eg solvent, reaction temperature, etc.) can also be referred to in the description of Method 1. Method D Compound (IX) or a salt thereof can be prepared by carrying out a reduction reaction with respect to compound (XII) or a salt thereof. This reaction can be carried out in a similar manner to Method B mentioned above, so the reagents used and the reaction conditions (eg solvent, reaction temperature, etc.) can also be referred to in the description in Method B. Method E Compound (IIa) or a salt thereof can be prepared by carrying out the elimination reaction of an amino protecting group with respect to compound (XIII) or a salt thereof. This reaction can be carried out in the manner described in Preparation Examples 5 or 6 or in a similar manner. Method F Compound (Xb) or a salt thereof can be prepared by reacting a reactive derivative thereof in the compound (Xa) or an amino group, or a salt thereof with a reactive derivative thereof in the compound (IV) or a carboxy group, or a salt thereof. This reaction can be carried out in the manner described in Preparation Example 16 or in a similar manner. Method G Compound (XIIa) or a salt thereof can be prepared by reacting compound (XIV) with compound (XV) or a salt thereof. This reaction can be carried out in the manner described in Preparation Example 1 or in a similar manner. Method H Compound (IX) or a salt thereof can be prepared by reacting compound (XVII) or a salt thereof with compound (XVIII) or a salt thereof. This reaction can be carried out in the manner described in Preparation Example 3 or in a similar manner. Method I Compound (Xc) or a salt thereof can be prepared by reacting compound (XIX) or a salt thereof with compound (XX). This reaction can be carried out in the manner described in Preparation Example 10 or in a similar manner. Method J Compound (V) or a salt thereof can be prepared by carrying out a halogenation reaction with respect to compound (XI) or a salt thereof. This reaction can be carried out in the manner described in Preparation 25 or in a similar manner. Method K Compound (XXIIa) or a salt thereof can be prepared by reacting compound (XIV) with compound (XXI) or a salt thereof. This reaction can be carried out in the manner described in Preparation Example 2 or in a similar manner. Method L Compound (XIIb) or a salt thereof can be prepared by reacting compound (XXII) or a salt thereof with compound (XXIII) or a salt thereof. This reaction can be carried out in the manner described in Preparation 12 or in a similar manner. Suitable salts of the target compounds and starting compounds in the methods (1) to (5) and (A) to (L) may be referred to as exemplified for compound (I). Novel pyridopyrazine derivatives (I) and pharmaceutically acceptable salts thereof have little potent inhibitory activity against phosphodiesterase III (PDE III), but phosphodiesterase IV (PDE IV) and tumors Necrosis factor (TNF) shows strong inhibitory activity. That is, pyridopyrazine derivatives (I) and pharmaceutically acceptable salts thereof are selective inhibitors of phosphodiesterase IV (PDE IV) and inhibitors of production of tumor necrosis factor (TNF). Thus, the novel pyridopyrazine derivatives (I) and pharmaceutically acceptable salts thereof include chronic inflammatory diseases (eg, rheumatoid arthritis, osteoarthritis, emphysema, chronic bronchiolitis, etc.), osteoporosis, transplant rejection, asthma, eosinophilia, cysts Sexual fibrosis, hepatitis, pancreatitis, nephritis, endotoxin shock, special autoimmune diseases (e.g. ankylosing spondylitis, autoimmune blood diseases (e.g. hemolytic anemia, aplastic anemia, true erythrocytic anemia, idiopathic thrombocytopenia), systemic erythema Lupus, polychondritis, scleroderma, Wegener granulamotosis, dermatitis, chronic active hepatitis, gastromyopathy, atopic dermatitis, psoriasis, idiopathic sprue, autoimmune inflammatory bowel disease (e.g. ulcerative colitis, Crohn ), Etc.), endocrine eyelids, Grave's disease, sarcoids, multiple sclerosis, primary biliary cirrhosis, diabetes (e.g. combustible diabetes (type I diabetes mellitus)) ], PDE- such as Reiter's syndrom, non-infective uveitis, autoimmune keratitis (eg, dry keratoconjunctivitis, spring keratoconjunctivitis, etc.), interstitial pulmonary fibrosis, psoriatic arthritis, etc., cancer cachexia, AIDS cachexia, thrombosis, etc. It can be used to prevent and treat IV and TNF intervening diseases. Pharmacological test data for representative compounds of pyridopyrazine (I) are shown below to confirm the utility of the pyridopyrazine derivatives (I) and pharmaceutically acceptable salts thereof. (a) inhibition of U937 phosphodiesterase IV (PDE IV) 1. Test method: The harvested U937 was frozen at −80 ° C. and then thawed to disrupt cells. Crushed cell pellets were washed with phosphate-buffered saline (PBS). Washed cell pellets in homogeneous buffer (0.5% deoxycholate [DOC] in PBS, 5 mM 2-mertoptoethanol, 1 μM leupeptin, 100 μM PMSF, 20 μM p-tosyl-L-lysine-chloromethyl ketone [TLCK]). ]) Was homogenized with a Downs homogenizer (20 strokes). The homogenate was centrifuged at 100,000 g x 90 min (4 ° C.) and the supernatant with PDE IV activity was dialyzed with the same dialysis buffer as the homogeneous buffer except for the absence of DOC. The dialysis supernatant of the homogenate is stored as a PDE IV enzyme sample in the freezer compartment (-80 ° C.). Enzyme samples were diluted with test buffer (10 mM Tris-HCl, 5 mM MgCl, 1 mM 2-mercaptoethanol [H 8.0]). In advance, dilution ratios were determined for all new lots of homogeneous samples. A portion of the enzyme sample was boiled for 10 minutes to make a blank. The test compound was dissolved in dimethylsulfoxide (DMSO) at a concentration of 4 x 10 (-2) [M] (final concentration 1 x 10 (-5) [M]), followed by serial dilutions in DMSO to give the desired Made to concentration. Each concentration of diluted compound was further diluted 1: 500 in test buffer (0.2% DMSO). The final DMSO concentration in vitro is 0.025%. Repeatedly, 50 μl of control or blank compound or test buffer, 50 μl of 8 × 10 (-5) [M] CI-930 (final 10 μM) (CI-930 is a PDE III inhibitor) and enzyme sample or blank 200 μl of the boiling boiling enzyme sample was added sequentially to the glass tube at 0 ° C. (all concentrations were given as final concentrations in vitro). The reaction tube was preincubated for 5 minutes in a water bath (30 ° C.) and then [ 3 H] -cAMP (37.0 MBq / ml [ 3 H] -cAMP: 4 μM cold cAMP = 1: 800) was added. After 15 minutes, 2.5 units / ml alkaline phosphatase were added to the reaction mixture and allowed to react for 15 minutes. Dowex 1 × 8 gel was added to the reaction mixture and vortexed uniformly. After the mixture was centrifuged at 1000 rpm x 5 minutes, 500 μl of the supernatant was added to 10 ml of scintillation fluid in a suitable vial, vortexed, and then counted [ 3 H]. Inhibitory activity was calculated according to the following scheme: % Inhibition = 100-{(average cpm [test compound] -average cpm [blank (boiling enzyme)]) / (average cpm [control (does not contain compound)]-average cpm [blank (boiling enzyme])} x 100 2. Test compound: (a) 4- [3- [3-[(E) -3- (6-acetamido-3-pyridyl) acryloylamino] phenyl] phenyl] -2- (3-pyridylmethyl)- 3-oxo-3,4-dihydropyrido [2,3-b] pyrazine 3. Test result: Test compoundIC 50 (M) (a)1.6 x 10 -8 (b) inhibition of TNF-α production in human mononuclear cells 1. Test Method: Blood was drawn from healthy volunteers with heparin. Mononuclear cell (MNC) fractions were obtained by gradient centrifugation (1800 rpm, 15 min) and diluted in an equal volume of RPMI-1640 culture medium on Ficoll-Paque (Pharmacia LKB Biotechnology). MNC was washed twice with RPMI-1640. MNCs were then resuspended in RPMI-1640 culture medium supplemented with 2 mM L-glutamine and 1% fetal calf serum. MNC was added at or without addition of 1 μg / ml lipopolysaccharide (LPS) (from E. coli) and various amounts of test compound at 3 × 10 5 cells / well concentration in 96-well micro culture plates. Incubate for 16 hours at. After completion of incubation, a decanted solution was obtained and its TNF-α activity was measured by enzyme-labeled immunoassay (ELISA). ELISA was performed using a TNF-α ELISA kit (Otsuka Pharmaceutical Co., Ltd.). 2. Test compound: (a) 4- [3- [3-[(E) -3- (6-acetamido-3-pyridyl) acryloylamino] phenyl] phenyl] -2- (3-pyridylmethyl)- 3-oxo-3,4-dihydropyrido [2,3-b] pyrazine 3. Test result: Test compoundIC 50 (M) (a)2.4 x 10 -8 In the case of therapeutic administration, the desired compound (I) or a pharmaceutically acceptable salt thereof of the present invention is a conventional pharmaceutically acceptable such as an organic or inorganic solid, or liquid excipient suitable for oral, parenteral or external administration. It is used in the form of a conventional pharmaceutical formulation as a mixture with a carrier. Pharmaceutical formulations may be formulated in solid forms such as granules, capsules, tablets, dragees or suppositories, or in liquid forms such as solutions for injection, ingestion or instillation (such as suspensions) or emulsions. If desired, the formulation may include auxiliary substances such as stabilizers, wetting or emulsifiers, buffers, or other commonly used additives. The active ingredient may generally be administered 1 to 4 times per day in unit doses of 0.001 to 500 mg / kg body weight, preferably 0.01 to 10 mg / kg body weight. However, the average dose may be increased or decreased depending on the age, weight and condition of the patient or the method of administration. Preferred specific examples of the target compound (I) are as follows. R 1 is pyridyl (lower) alkyl, N-oxidodopyridyl (lower) alkyl or imidazolyl (lower) alkyl, R 2 is aminophenyl, [lower alkanoylamino] phenyl, [[[halophenyl] (lower) alkenoyl] amino] phenyl, [[yridyl (lower) alkenoyl] amino] phenyl, [[[N-oxa Idopyridyl] (lower) alkenoyl] amino] phenyl, [[[acylaminopyridyl] (lower) alkenoyl] amino] phenyl (more preferably [[[[lower alkanoylamino] pyridyl] (lower) ) Alkenoyl] amino] phenyl), [[yridylthiazolyl] carbonylamino] phenyl, naphthyl with lower alkoxy and halogen, [dihalophenyl] (lower) alkenyl, [N-oxidopyridyl] (Lower) alkenyl, [aminopyridyl] (lower) alkenyl, [[acylamino] pyridyl] (lower) alkenyl (more preferably [[lower alkanoylamino] pyridyl] (lower) alkenyl Or [[mono (or di or tri) halo (lower) alkanoylamino] pyridyl] (lower) alkenyl; most preferably [[lower alkanoylamino] pyridyl] (lower) alkenyl or [[tri Halo (lower) alkanoylamino] Pyridyl] (lower) alkenyl), [carboxypyridyl] (lower) alkenyl, [esterified carboxypyridyl] (lower) alkenyl (more preferably [lower alkoxycarbonylpyridyl] (lower) Alkenyl), [[yridyl (lower) alkenyl] pyridyl] (lower) alkenyl, [[carboxy (lower) alkenyl] pyridyl] (lower) alkenyl, [[esterified carboxy (lower) Alkenyl] pyridyl] (lower) alkenyl (more preferably [[lower alkoxycarbonyl (lower) alkenyl] pyridyl] (lower) alkenyl), [yridyl (lower) alkenyl] pyridyl, Lower alkylbenzothiazolyl or halopyridylcarbonylamino, Provided that when R 2 is [[4-pyridyl (lower) alkenoyl] amino] phenyl, aminophenyl, [lower alkanoylamino] phenyl or [dihalophenyl] (lower) alkenyl, then R 1 is N- Oxidopyridyl (lower) alkyl or imidazolyl (lower) alkyl. The following Preparation Examples and Examples are provided for the purpose of illustrating the present invention in more detail. Preparation Example 1 3-nitrostyrene (7.0 g), 2-acetamido-5-bromopyridine (10.1 g), tetra-n-butylammonium chloride (13.1 g), palladium in N, N-dimethylformamide (70 mL) (II) A mixture of acetate (0.08 g) and sodium bicarbonate (9.87 g) was stirred at 110 ° C. for 6 hours. The reaction mixture was poured into ice water, precipitated crystals were collected, washed with water and dried to afford 3-[(E) -2- (6-acetamido-3-pyridyl) vinyl] nitrobenzene (12.0 g). . NMR (DMSO-d 6, δ): 2.11 (3H, s), 7.44 (1H, d, J = 16 Hz), 7.50 (1H, d, J = 16 Hz), 7.68 (1H, dd, J = 8, 8 Hz ), 8.04 (1H, d, J = 8 Hz), 8.11 (3H, m), 8.43 (1H, m or dd, J = 1, 1 Hz), 8.55 (1H, s, or d, J = 1 Hz). Preparation Example 2 3-nitrostyrene (5.36 mL), 3,5-dibromopyridine (10.0 g), palladium (II) acetate (259 mg), tetra-n-butylammonium in N, N-dimethylformamide (50 mL) A mixture of chloride (10.7 g) and sodium bicarbonate (8.07 g) was stirred at 120 ° C for 4 hours. The mixture was poured into sodium bicarbonate solution and extracted twice with ethyl acetate. The combined organic solutions were washed with sodium bicarbonate solution and brine, dried over magnesium sulfate and concentrated. The resulting solid was washed with diisopropyl ether to give 3-bromo-5-[(E) -2- (3-nitrophenyl) vinyl] pyridine (5.74 g). NMR (CDCl 3, δ): 7.1-7.3 (2H, m), 7.59 (1H, t, J = 8 Hz), 7.82 (1H, d, J = 8 Hz), 8.02 (1H, t, J = 2 Hz), 8.18 (1H, dd, J = 2, 8 Hz), 8.39 (1H, t, J = 2 Hz), 8.11 (1H, d, J = 2 Hz), 8.67 (1H, d, J = 2 Hz), Preparation Example 3 3,5-dibromopyridine (9.9 g), 3-aminophenyl-dihydroxyboranehemisulfate (7.77 g) in methanol (21 mL) and toluene (85 mL), tetrakis (triphenylphosphine) palladium A mixture of (0) (1.06 g) and 2M aqueous sodium bicarbonate solution (42 mL) was stirred at 80 ° C for 4.5 h. The mixture was poured into sodium bicarbonate solution and extracted twice with ethyl acetate. The combined organic solutions were washed with sodium bicarbonate solution and brine, dried over magnesium sulfate and concentrated. The residue was chromatographed on silica gel column (4% methanol in chloroform) to give 3- (3-aminophenyl) -5-bromopyridine (4.31 g). NMR (DMSO-d 6, δ): 5.24 (2H, s), 6.64 (1H, m), 6.8-6.9 (2H, m), 7.14 (1H, t, J = 8 Hz), 8.19 (1H, t, J = 2 Hz), 8.66 (1H, d, J = 2 Hz), 8.78 (1H, d, J = 2 Hz). Preparation Example 4 According to a method similar to Preparation Example 3, the following compounds were obtained. (1) 3- (3-acetamidophenyl) aniline NMR (DMSO-d 6, δ): 2.05 (3H, s), 5.17 (2H, s), 6.54 (1H, m), 6.70 (1H, m), 6.80 (1H, m), 7.10 (1H, dd , J = 8, 8 Hz), 7.20 (1 H, m), 7.32 (1 H, dd, J = 8, 8 Hz), 7.50 (1 H, m), 7.82 (1 H, m). MASS (m / z): 227 (M + l). (2) 3- (3-aminophenyl) -6-methoxynaphthalene NMR (DMSO-d 6, δ): 3.89 (3H, s), 5.16 (2H, s), 6.56 (1H, m), 6.90 (1H, m), 6.96 (1H, m), 7.12 (1H, d , J = 8 Hz), 7.18 (1H, dd, J = 8, 2 Hz), 7.33 (1H, m), 7.69 (1H, m), 7.88 (2H, m), 8.00 (1H, m). Preparation Example 5 3-[(E) -2- (6-acetamido-3-pyridyl) vinyl] nitrobenzene (3.0 g), iron powder (1.48 g), ammonium chloride (0.57 g), ethanol (30 mL) and The mixture of water (9 mL) was stirred at reflux for 5 hours. The reaction was filtered and concentrated, then extracted with chloroform. The extract was chromatographed on a silica gel column (20 g, chloroform-methanol 1: 100 as eluent) to give an oil. Crystallization with methanol gave 3-[(E)-(6-acetamido-3-pyridyl) vinyl] aniline (2.4 g). NMR (DMSO-d 6, δ): 2.10 (3H, s), 5.10 (2H, s), 6.50 (1H, m), 6.73 (2H, m), 7.05 (3H, m), 8.05 (2H, m ), 8.48 (1 H, m). Preparation Example 6 3-bromo-5-[(E) -2- (3-nitrophenyl) vinyl] pyridine (5.55 g), iron powder (3.05 g) and ammonium formate in ethanol (90 mL) and water (30 mL) (5.73 g) was stirred at 90 ° C. for 30 minutes. The mixture was filtered when hot. The filtrate was added to sodium bicarbonate solution and extracted twice with ethyl acetate. The combined organic solutions were washed with sodium bicarbonate solution and brine, dried over magnesium sulfate and concentrated to give 3-[(E) -2- (3-aminophenyl) vinyl] -5-bromopyridine (3.57 g). Obtained. NMR (DMSO-d 6, δ): 5.13 (2H, s), 6.54 (1H, d, J = 8 Hz), 6.79 (2H, m), 7.0-7.1 (2H, m), 7.37 (1H, d, J = 16 Hz), 8.35 (1H, d, J = 2 Hz), 8.56 (1H, d, J = 2 Hz), 8.74 (1H, s). Preparation Example 7 A mixture of 3-vinylaniline (8 g), 2-chloro-3-nitrophenyl (10.7 g) and potassium carbonate (18.6 g) in dioxane (80 mL) was stirred at reflux for 5 days. The reaction was extracted with chloroform, washed with water, dried over magnesium sulfate and then evaporated. After evaporation of the solvent, the crude residue was crystallized with methanol to give 2- (3-vinylphenylamino) -3-nitropyridine as orange crystals (12.9 g). NMR (CDCl 3, δ): 5.30 (1H, d, J = 12 Hz), 5.79 (1H, d, J = 16 Hz), 6.75 (1H, dd, J = 16, 12 Hz), 6.85 (1H, dd, J = 8, 4 Hz), 7.25 (2H, m), 7.36 (1H, dd, J = 8, 8 Hz), 7.58 (1H, m), 7.67 (1H, s), 8.52 (2H, m). Preparation Example 8 3-[(E) -2- (3-aminophenyl) vinyl] -5-bromopyridine (3.5 g) in 1,4-dioxane (30 mL), 2-chloro-3-nitropyridine (2.22 g ) And potassium carbonate (2.64 g) were stirred at reflux for 22 hours. The mixture was filtered and the filtrate was concentrated. The resulting solid was washed with ethanol to give 2- [3-[(E) -2- (5-bromopyridin-3-yl) vinyl] phenylamino] -3-nitropyridine (1.63 g). NMR (CDCl 3, δ): 6.89 (1H, dd, J = 5, 8 Hz), 7.03 (1H, d, J = 16 Hz), 7.20 (1H, d, J = 16 Hz), 7.3-7.5 (2H, m ), 7.60 (1H, d, J = 8 Hz), 7.87 (1H, s), 8.00 (1H, s), 8.5-8.6 (2H, m), 8.63 (1H, s). Preparation Example 9 The following compounds were obtained following the method analogous to Preparation Example 7 or 8. (1) 2- [3-[(E) -2- (6-acetamido-3-pyridyl) vinyl] phenylamino] -3-nitropyridine. NMR (DMSO-d 6, δ): 2.10 (3H, s), 7.00 (1H, dd, J = 8, 5 Hz), 7.22 (1H, d, J = 16 Hz), 7.30 (1H, d, J = 16 Hz ), 7.39 (2H, m), 7.60 (1H, m), 7.84 (1H, m), 8.06 (2H, m), 8.53 (3H, m). (2) 2- [3- (5-bromopyridin-3-yl) phenylamino] -3-nitropyridine. NMR (CDCl 3, δ): 6.90 (1H, dd, J = 5, 8 Hz), 7.38 (1H, d, J = 8 Hz), 7.52 (1H, t, J = 8 Hz), 7.69 (1H, d, J = 8Hz), 7.98 (1H, m), 8.07 (1H, t, J = 2Hz), 8.5-8.6 (2H, m), 8.69 (1H, d, J = 2Hz), 8.80 (1H, d, J = 2 Hz). (3) 2- [3- (3-acetamidophenyl) phenylamino] -3-nitropyridine. NMR (CDCl 3, δ): 2.20 (3H, s), 6.83 (1H, dd, J = 8, 5 Hz), 7.3-7.4 (4H, m), 7.45 (1H, dd, J = 8, 8 Hz), 7.52 (1 H, m), 7.67 (1 H, m), 7.75 (1 H, s), 7.83 (1 H, m), 8.52 (2 H, m). (4) 2- [3- (2-methylbenzothiazol-6-yl) phenylamino] -3-nitropyridine. NMR (DMSO-d 6, δ): 2.80 (3H, s), 7.00 (1H, dd, J = 8, 5 Hz), 7.50 (2H, m), 7.75 (2H, m), 7.96 (2H, m) , 8.35 (1H, s), 8.55 (2H, m). (5) 2- [3- (2-methylbenzothiazol-5-yl) phenylamino] -3-nitropyridine. NMR (DMSO-d 6, δ): 2.81 (3H, s), 7.01 (1H, dd, J = 8, 5 Hz), 7.50 (2H, m), 7.72 (2H, m), 8.02 (1H, s) , 8.12 (1H, doublet, J = 8 Hz), 8.21 (1H, s), 8.53 (2H, m). (6) 2- [3- (6-methoxy-2-naphthyl) phenylamino] -3-nitropyridine. NMR (DMSO-d 6, δ): 3.90 (3H, s), 7.01 (1H, m), 7.20 (1H, m), 7.37 (1H, m), 7.50 (1H, dd, J = 8, 8 Hz) , 7.57 (1H, m), 7.73 (1H, m), 7.84 (1H, m), 7.93 (2H, m), 8.04 (1H, m), 8.18 (1H, s), 8.56 (2H, m). Preparation Example 10 2- (3-vinylphenylamino) -3-nitropyridine (12.9 g), 3-bromopyridine (12.7 g), palladium (II) acetate (0.24 g), copper iodide (I) (0.10 g), tri A mixture of -o-tolylphosphine (0.65 g), triethylamine (25 mL) and acetonitrile (150 mL) was stirred overnight under reflux under nitrogen. After removing the solvent, the crude residue was chromatographed on silica gel (450 g, chloroform as eluent) to give 2- [3-[(E) -2- (3-pyridyl) vinyl] phenylamino] -3-nitro Pyridine was obtained as reddish orange crystals (11.5 g). NMR (DMSO-d 6, δ): 7.02 (1H, dd, J = 8, 5 Hz), 7.30 (1H, d, J = 16 Hz), 7.40 (4H, m), 7.65 (1H, m), 7.88 ( 1H, m), 8.05 (1H, d, J = 8 Hz), 8.46 (1H, m), 8.55 (2H, m), 8.80 (1H, m). Preparation Example 11 According to a method similar to Preparation Example 10, the following compounds were obtained. 2- [3-[(E) -2- (5-methoxycarbonylpyridin-3-yl) vinyl] phenylamino] -3-nitropyridine NMR (DMSO-d 6, δ): 3.92 (3H, s), 7.02 (1H, dd, J = 8, 5 Hz), 7.42 (3H, m), 7.56 (1H, d, J = 16 Hz), 7.68 ( 1 H, m), 7.93 (1 H, m), 8.55 (3 H, m), 8.95 (1 H, br s), 9.05 (1 H, br s). Preparation Example 12 2- [3-[(E) -2- (5-bromopyridin-3-yl) vinyl] phenylamino] -3-nitropyridine (800 mg) in N, N-dimethylformamide (4 mL), A mixture of 4-vinylpyridine (233 mg), palladium (II) acetate (27 mg), tetra-n-butylammonium chloride (616 mg) and sodium bicarbonate (432 mg) was stirred at 120 ° C. for 4 hours. The mixture was poured into sodium bicarbonate solution and extracted twice with ethyl acetate. The combined organic solutions were washed with aqueous sodium bicarbonate and brine, dried over magnesium sulfate and concentrated. The residue was crystallized from ethanol to give 2- [3-[(E) -2- [5-[(E) -2- (4-pyridyl) vinyl] pyridin-3-yl] vinyl] phenylamino] -3 Nitropyridine (346 mg) was obtained. NMR (CDCl 3, δ): 6.89 (1H, dd, J = 5, 8 Hz), 7.1-7.5 (8H, m), 7.62 (1H, d, J = 8 Hz), 7.87 (1H, s), 8.00 ( 1H, s), 8.5-8.7 (6H, m). Preparation Example 13 The following compounds were obtained following the method analogous to Preparation Example 12. (1) 2- [3-[(E) -2- [5-[(E) -2-methoxycarbonylvinyl] pyridin-3-yl] vinyl] phenylamino] -3-nitropyridine. NMR (CDCl 3, δ): 3.83 (3H, s), 6.59 (1H, d, J = 16 Hz), 6.89 (1H, dd, J = 5, 8 Hz), 7.11 (1H, d, J = 16 Hz), 7.23 (1H, d, J = 16 Hz), 7.3-7.45 (2H, m), 7.61 (1H, d, J = 8 Hz), 7.72 (1H, d, J = 16 Hz), 7.88 (1H, s), 7.96 (1H, t, J = 2 Hz), 8.5-8.6 (2H, m), 8.62 (1H, d, J = 2 Hz), 8.73 (1H, d, J = 2 Hz). (2) 2- [3- [5-[(E) -2- (4-pyridyl) vinyl] pyridin-3-yl] phenylamino] -3-nitropyridine. NMR (CDCl 3, δ): 6.90 (1H, dd, J = 5, 8 Hz), 7.15-7.6 (6H, m), 7.52 (1H, dt, J = 8, 2 Hz), 7.96 (1H, t, J = 2Hz), 8.06 (1H, t, J = 2Hz), 8.5-8.7 (4H, m), 8.76 (1H, d, J = 2Hz), 8.82 (1H, d, J = 2Hz), 10.25 (1H, s). Preparation Example 14 2- [3- (6-methoxy-2-naphthyl) phenylamino] -3-nitropyridine (5.2 g), N-bromosuccinimide (3.24 g) and benzoyl peroxide in chloroform (30 mL) (678 mg) was refluxed for 3 hours. The mixture was concentrated in vacuo and purified by column chromatography (silica gel) to give 2- [3- (5-bromo-6-methoxy-2-naphthyl) phenylamino] -3-nitropyridine (3.3 g) Obtained. NMR (CDCl 3, δ): 4.05 (3H, s), 6.87 (1H, dd, J = 8, 6 Hz), 7.31 (1H, d, J = 8 Hz), 7.48-7.53 (2H, m), 7.65- 7.73 (1H, m), 7.83-7.90 (2H, m), 7.95 (1H, s), 8.00 (1H, s), 8.29 (1H, d, J = 8 Hz), 8.45-8.56 (2H, m). Preparation Example 15 A solution of 2- [3- (3-acetamidophenyl) phenylamino] -3-nitropyridine (10 g) in 3N hydrochloric acid (100 mL) was refluxed for 2 hours. The cooling reaction was adjusted to pH 8 with saturated sodium bicarbonate solution, the precipitated reddish crystals collected, washed with water and dried to give 2- [3- (3-aminophenyl) phenylamino] -3-nitropyridine (9.53 g). ) Was obtained. NMR (DMSO-d 6, δ): 6.89 (1H, m), 7.01 (1H, dd, J = 8, 5 Hz), 7.17 (2H, m), 7.30 (1H, m), 7.36 (1H, m) , 7.45 (1H, doublet of doublets, J = 8, 8 Hz), 7.68 (1H, m), 7.88 (1H, m), 8.55 (2H, m). Preparation Example 16 To an ice cold suspension of 3- (2-pyridyl) acrylic acid (1.07 g) in methylene chloride (80 mL) was added triethylamine (1.46 g) and pivaloyl chloride (0.87 g) and the mixture was stirred for 2 hours. It was. After obtaining a clear reaction mixture, 2- [3- (3-aminophenyl) phenylamino] -3-nitropyridine (2.0 g) was added and stirred at reflux overnight. The reaction was chromatographed on silica gel (chloroform-methanol 50: 1 as eluent) to give 2- [3- [3-[(E) -3- (2-pyridyl) acryloylamino] phenyl] phenylamino]- 3-nitropyridine was obtained as orange crystals (2.85 g). NMR (DMSO-d 6, δ): 7.02 (1H, dd, J = 8, 5 Hz), 7.35 (1H, d, J = 16 Hz), 7.42 (4H, m), 7.50 (1H, m), 7.65 ( 2H, m), 7.71 (2H, m), 7.88 (1H, m), 7.94 (1H, s), 8.08 (1H, s), 8.55 (2H, m), 8.66 (1H, m). Preparation Example 17 According to a method similar to Preparation 16, the following compounds were obtained. (1) 2- [3- [3-[(E) -3- (6-acetamido-3-pyridyl) acryloylamino] phenyl] phenylamino] -3-nitropyridine. NMR (DMSO-d 6, δ): 2.11 (3H, s), 6.84 (1H, d, J = 16 Hz), 7.01 (1H, dd, J = 8, 5 Hz), 7.35-7.50 (4H, m), 7.60 (1H, d, J = 16 Hz), 7.70 (2H, m), 7.91 (1H, m), 8.05 (2H, m), 8.18 (1H, m), 8.55 (3H, m). (2) 2- [3- [3-[(E) -3- (4-pyridyl) acryloylamino] phenyl] phenylamino] -3-nitropyridine NMR (DMSO-d 6, δ): 7.02 (1H, dd, J = 8, 5 Hz), 7.05 (1H, d, J = 15 Hz), 7.45 (4H, m), 7.60 (3H, m), 7.72 ( 2H, m), 7.93 (1H, m), 8.05 (1H, m), 8.55 (2H, m), 8.65 (2H, m). Preparation Example 18 M-chloroperbenzoic acid (1.81 g) in a solution of 3-nitro-2- [3-[(E) -2- (3-pyridyl) vinyl] phenylamino] pyridine (2.22 g) in dichloromethane (70 mL). ) Was added. The mixture was stirred at rt for 1 h, then poured into aqueous sodium bicarbonate and extracted with chloroform. The organic solution was washed with aqueous sodium bicarbonate and brine, dried over magnesium sulfate and then concentrated. The residue was chromatographed on a silica gel column (8% methanol in chloroform) to give 3-nitro-2- [3-[(E) -2- (1-oxido-3-pyridyl) vinyl] phenylamino] pyridine ( 1.51 g) was obtained. NMR (CDCl 3, δ): 6.85-7.0 (2H, m), 7.15-7.5 (5H, m), 7.62 (1H, d, J = 8 Hz), 7.88 (1H, s), 8.12 (1H, d, J = 5 Hz), 8.38 (1 H, s), 8.5-8.6 (2 H, m). Preparation Example 19 The following compounds were obtained following the procedure similar to Preparation Example 18. (1) 3-nitro-2- [3-[(E) -2- (1-oxido-4-pyridyl) vinyl] phenylamino] pyridine. NMR (CDCl 3, δ): 6.89 (1H, dd, J = 5, 8 Hz), 7.01 (1H, d, J = 16 Hz), 7.20 (1H, d, J = 16 Hz), 7.3-7.5 (4H, m ), 7.84 (1H, s), 8.19 (1H, d, J = 7 Hz), 8.5-8.6 (2H, m). (2) 2- [3- [3-[(E) -3- (1-oxido-4-pyridyl) acryloylamino] phenyl] phenylamino] -3-nitropyridine. NMR (DMSO-d 6, δ): 6.90 (1H, d, J = 16 Hz), 7.01 (1H, dd, J = 8, 5 Hz), 7.45 (4H, m), 7.57 (1H, d, J = 16 Hz ), 7.65 (2H, m), 7.70 (2H, m), 7.92 (1H, s), 8.03 (1H, s), 8.25 (2H, m), 8.55 (2H, m). Preparation Example 20 2- [3-[(E) -2- (2-acetamido-3-pyridyl) vinyl] phenylamino] -3-aminopyridine (1.86 g), iron powder (1.39 g), ammonium chloride (0.26 g), a mixture of ethanol (20 mL) and water (6 mL) was stirred under reflux for 1 hour. The reaction was filtered, concentrated and extracted with chloroform. The extract was washed with saturated sodium bicarbonate solution, dried and evaporated to 2- [3-[(E) -2- (6-acetamido-3-pyridyl) vinyl] phenylamino] -3-aminopyridine Was obtained as dark purple crystals (1.59 g). NMR (DMSO-d 6, δ): 2.10 (3H, s), 5.08 (2H, s), 6.64 (1H, dd, J = 8, 5 Hz), 6.90 (1H, d, J = 8 Hz), 7.11 ( 2H, m), 7.23 (2H, m), 7.55 (2H, m), 7.77 (2H, m), 8.07 (2H, s), 8.50 (1H, s). Preparation Example 21 2- [3-[(E) -2- [5-[(E) -2- (4-pyridyl) vinyl] pyridin-3-yl] vinyl] in ethanol (6 mL) and water (2 mL)] A mixture of phenylamino] -3-nitropyridine (331 mg), iron powder (132 mg) and ammonium formate (297 mg) was stirred at 90 ° C. for 30 minutes. The mixture was filtered when hot. The filtrate was added to an aqueous sodium bicarbonate solution and extracted twice with ethyl acetate. The combined organic solutions were washed with sodium bicarbonate and brine, dried over magnesium sulfate and then concentrated. The resulting solid was washed with diisopropyl ether to 3-amino-2- [3-[(E) -2- [5-[(E) -2- (4-pyridyl) vinyl] pyridin-3-yl ] Vinyl] phenylamino] pyridine (270 mg) was obtained. NMR (DMSO-d 6, δ): 5.10 (2H, s), 6.67 (1H, dd, J = 5, 8 Hz), 6.92 (1H, d, J = 8 Hz), 7.1-7.3 (3H, m), 7.4-7.7 (7H, m), 7.81 (1H, s), 7.90 (1H, s), 8.42 (1H, s), 8.61 (1H, d, J = 5 Hz), 8.69 (1H, s), 8.72 ( 1H, s). Preparation Example 22 The following compounds were obtained following the method analogous to Preparation Example 20 or 21. (1) 2- [3- [3-[(E) -3- (2-pyridyl) acryloylamino] phenyl] phenylamino] -3-aminopyridine. NMR (DMSO-d 6, δ): 6.75 (1H, m), 7.0-8.2 (15H, m), 8.65 (1H, m). (2) 2- [3- [3-[(E) -3- (6-acetamido-3-pyridyl) acryloylamino] phenyl] phenylamino] -3-aminopyridine. NMR (DMSO-d 6, δ): 2.12 (3H, s), 5.10 (2H, br s), 6.65 (1H, m), 6.88 (2H, m), 7.11 (1H, m), 7.38 (3H, m), 7.60 (4H, m), 7.88 (1H, m), 8.04 (2H, m), 8.15 (1H, m), 8.55 (1H, m). (3) 3-amino-2- [3-[(E) -2- [5-[(E) -2-methoxycarbonylvinyl] pyridin-3-yl] vinyl] phenylamino] pyridine. NMR (DMSO-d 6, δ): 3.77 (3H, s), 5.09 (2H, s), 6.65 (1H, dd, J = 5, 8 Hz), 6.9-7.0 (2H, m), 7.1-7.3 ( 3H, m), 7.45-7.6 (3H, m), 7.7-7.9 (3H, m), 8.52 (1H, s), 8.76 (2H, m). (4) 3-amino-2- [3- [5-[(E) -2- (4-pyridyl) vinyl] pyridin-3-yl] phenylamino] pyridine. NMR (DMSO-d 6, δ): 5.11 (2H, s), 6.67 (1H, dd, J = 5, 8 Hz), 7.94 (1H, dd, J = 2, 8 Hz), 7.26 (1H, d, J = 8Hz), 7.40 (1H, t, J = 8Hz), 7.5-7.7 (5H, m), 7.80 (1H, d, J = 8Hz), 7.9-8.0 (2H, m), 8.32 (1H, s) , 8.60 (1H, d, J = 5 Hz), 8.78 (1H, d, J = 2 Hz), 8.82 (1H, d, J = 2 Hz). (5) 3-amino-2- [3-[(E) -2- (1-oxidodo-3-pyridyl) vinyl] phenylamino] pyridine. NMR (DMSO-d 6, δ): 5.10 (2H, s), 6.64 (1H, dd, J = 5, 8 Hz), 6.92 (1H, d, J = 8 Hz), 7.1-7.7 (8H, m), 7.81 (2H, m), 8.11 (1H, doublet, J = 5 Hz), 8.53 (1H, s). (6) 3-amino-2- [3-[(E) -2- (1-oxido-4-pyridyl) vinyl] phenylamino] pyridine. NMR (DMSO-d 6, δ): 5.10 (2H, s), 6.66 (1H, dd, J = 5, 8 Hz), 6.92 (1H, d, J = 8 Hz), 7.1-7.2 (2H, m), 7.28 (1H, t, J = 8 Hz), 7.37 (1H, d, J = 16 Hz), 7.5-7.7 (4H, m), 7.8-7.9 (2H, m), 8.19 (1H, d, J = 5 Hz) . (7) 2- [3- (3-acetamidophenyl) phenylamino] -3-aminopyridine. NMR (CDCl 3, δ): 2.13 (3H, s), 3.50 (2H, br s), 6.33 (1H, s), 6.77 (1H, dd, J = 8, 5 Hz), 7.00 (1H, d, J = 8 Hz), 7.12 (1H, dd, J = 8, 2 Hz), 7.2-7.4 (5H, m), 7.50 (1H, m), 7.55 (1H, m), 7.61 (1H, s), 7.82 (1H , d, J = 5 Hz). (8) 2- [3- [3-[(E) -3- (1-oxido-4-pyridyl) acryloylamino] phenyl] phenylamino] -3-aminopyridine. NMR (DMSO-d 6, δ): 5.10 (2H, s), 6.64 (1H, dd, J = 8, 5 Hz), 6.90 (1H, d, J = 15 Hz), 6.93 (1H, d, J = 8 Hz ), 7.10 (1H, d, J = 8 Hz), 7.35 (2H, m), 7.45 (1H, dd, J = 8, 8 Hz), 7.53 (1H, d, J = 5 Hz), 7.58 (1H, d, J = 15 Hz), 7.67 (4H, m), 7.90 (2H, d, J = 8 Hz), 8.00 (1H, m), 8.26 (2H, d, J = 8 Hz). (9) 2- [3- (2-methylbenzothiazol-5-yl) phenylamino] -3-aminopyridine. NMR (DMSO-d 6, δ): 2.80 (3H, s), 5.12 (2H, s), 6.64 (1H, m), 6.92 (1H, m), 7.20 (1H, m), 7.35 (1H, m ), 7.52 (1H, m), 7.65 (1H, m), 7.71 (1H, m), 7.92 (1H, m), 8.00 (1H, m), 8.10 (2H, m). (10) 2- [3- (2-methylbenzothiazol-6-yl) phenylamino] -3-aminopyridine. NMR (DMSO-d 6, δ): 2.80 (3H, s), 5.15 (2H, s), 6.65 (1H, m), 6.95 (1H, m), 7.25 (1H, m), 7.35 (1H, m ), 7.55 (1 H, m), 7.75 (2 H, m), 8.00 (3 H, m), 8.30 (1 H, m). (11) 2- [3-[(E) -2- (5-methoxycarbonylpyridin-3-yl) vinyl] phenylamino] -3-aminopyridine. NMR (DMSO-d 6, δ): 3.92 (3H, s), 5.10 (2H, s), 6.65 (1H, dd, J = 8, 5H), 6.92 (1H, d, J = 8 Hz), 7.18 ( 1H, m), 7.28 (2H, m), 7.50 (1H, d, J = 16 Hz), 7.54 (1H, m), 7.60 (1H, m), 7.80 (1H, s), 7.88 (1H, m) , 8.50 (1H, m), 8.94 (1H, s), 9.05 (1H, d, J = 3 Hz). (12) 2- [3- (6-methoxy-2-naphthyl) phenylamino] -3-aminopyridine. NMR (CDCl 3, δ): 3.45 (2H, br s), 3.93 (3H, s), 6.30 (1H, s), 6.80 (1H, dd, J = 8, 5 Hz), 7.04 (1H, m), 7.16 (2H, m), 7.30 (2H, m), 7.39 (1H, m), 7.54 (1H, m), 7.71 (1H, m), 7.79 (2H, m), 7.87 (1H, m), 7.98 (1H, s). (13) 2- [3- (5-bromo-6-methoxy-2-naphthyl) phenylamino] -3-aminopyridine. NMR (CDCl 3, δ): 3.45 (1H, br s), 4.03 (3H, s), 6,34 (1H, br s), 6.79 (1H, dd, J = 6, 8 Hz), 7.02 (1H, dd, J = 8, 8 Hz), 7.25-7.33 (4H, m), 7.35-7.40 (1H, m), 7.57 (1H, m), 7.79-7.87 (3H, m), 7.95 (1H, m), 8.25 (1 H, m). MASS (m / z): 420 (M + 1), 422. Preparation Example 23 A mixture of 2- [3- (6-methoxy-2-naphthyl) phenylamino] -3-aminopyridine (60 g) and pyruvic acid (18.6 g) in methanol was refluxed for 5 hours. The mixture was cooled down and crystallized. Suction collection of 2-methyl-4- [3- (6-methoxy-2-naphthyl) phenyl] -3-oxo-3,4-dihydropyrido [2,3-b] pyridine (12.6 g) It was. NMR (DMSO-d 6, δ): 2.51 (3H, s), 3.88 (3H, s), 7.20 (1H, m), 7.35 (2H, m) 7.40 (1H, dd, J = 8, 5 Hz), 7.66 (1H, doublet of doublets, J = 8, 8 Hz), 7.81 (2H, m) 7.90 (3H, m), 8.19 (1H, s), 8.23 (1H, m), 8.40 (1H, m). Preparation Example 24 According to a method similar to Preparation 23, the following compound was obtained. 4- [3- (3-acetamidophenyl) phenyl] -2- (3-pyridylmethyl) -3-oxo-3,4-dihydropyrido [2,3-b] pyrazine. mp: 190-193 ℃ NMR (CDCl 3, δ): 2.13 (3H, s), 4.32 (2H, s), 7.2-7.35 (5H, m), 7.45 (2H, m), 7.55 (1H, s), 7.62 (1H, dd , J = 8, 8 Hz), 7.70 (2H, m), 7.82 (1H, m), 8.18 (1H, d, J = 8 Hz), 8.41 (1H, m), 8.49 (1H, d, J = 5 Hz) , 8.73 (1 H, s). Preparation Example 25 2-methyl-4- [3- (6-methoxy-2-naphthyl) phenyl] -3-oxo-3,4-dihydropyrido [2,3-b] pyrazine in chloroform (30 mL) 3.4 g), a mixture of N-bromosuccinimide (3.08 g) and benzoylperoxide (837 mg) was refluxed for 3 hours. The mixture was concentrated in vacuo and purified by column chromatography (silica gel) to give 2-bromomethyl-4- [3- (6-methoxy-5-bromo-2-naphthyl) phenyl] -3-oxo -3,4-dihydropyrido [2,3-b] pyrazine (2.2 g) was obtained. NMR (CDCl 3, δ): 4.04 (3H, s), 4.71 (2H, s), 7.25-7.40 (3H, m), 7.65 (1H, m), 7.72 (1H, dd, J = 8, 8 Hz) , 7.85 (3H, m), 8.02 (1H, s), 8.27 (2H, m), 8.50 (1H, m). MASS (m / z): 550 (M + 1), 552, 554. Preparation Example 26 According to a method similar to Preparation Example 15, the following compound was obtained. 4- [3- (3-aminophenyl) phenyl] -2- (3-pyridylmethyl) -3-oxo-3,4-dihydropyrido [2,3-b] pyrazine. mp: 202-204 ℃ NMR (CDCl 3, δ): 3.73 (2H, s), 4.32 (2H, s), 6.15 (1H, m), 6.90 (1H, m), 6.98 (1H, d, J = 8 Hz), 7.25 (4H , m), 7.44 (1H, s), 7.62 (1H, dd, J = 8, 8 Hz), 7.70 (1H, d, J = 8 Hz), 7.82 (1H, d, J = 8 Hz), 8.18 (1H, d, J = 8 Hz), 8.43 (1H, d, J = 5 Hz), 8.50 (1H, m), 8.72 (1H, s). Example 1 3-amino-2- [3-[(E) -2- [5-[(E) -2- (4-pyridyl) vinyl] pyridin-3-yl] vinyl] phenylamino in ethanol (5 mL) ] A mixture of pyridine (260 mg) and 3-pyridylpyruvic acid (121 mg) was stirred at reflux for 5 hours. After removal of the solvent, the residue was chromatographed on a silica gel column (chloroform-methanol, 9: 1) and crystallized with methanol to give 2- (3-pyridylmethyl) -3-oxo-4- [3-[(E ) -2- [5-[(E) -2- (4-pyridyl) vinyl] pyridin-3-yl] vinyl] phenyl] -3,4-dihydropyrido [2,3-b] pyrazine ( 208 mg) was obtained. NMR (CDCl 3, δ): 4.33 (2H, s), 7.1-7.35 (7H, m), 7.40 (2H, d, H = 5 Hz), 7.47 (1H, s), 7.55-7.7 (2H, m) , 7.83 (1H, d, J = 8 Hz), 7.95 (1H, s), 8.20 (1H, d, J = 8 Hz), 8.44 (1H, d, J = 5 Hz), 8.52 (1H, d, J = 5 Hz ), 8.6-8.7 (4H, m), 8.74 (1H, s). Example 2 2- [3-[(E) -2- (6-acetamido-3-pyridyl) vinyl] phenylamino] -3-aminopyridine (1.5 g) and 3-pyridylpyruvic acid in ethanol (30 mL) (0.79 g) of the suspension was stirred under reflux for 8 hours. The cold reaction mixture was filtered and washed with ethanol to afford 2- (3-pyridylmethyl) -3-oxo-4- [3-[(E) -2- (6-acetamido-3-pyridyl) vinyl ] Phenyl] -3,4-dihydropyrido [2,3-b] pyrazine was obtained as colorless crystals (1.76 g). mp: 260-261 ° C. NMR (DMSO-d 6, δ): 2.10 (3H, s), 4.25 (2H, s), 7.27 (3H, m), 7.39 (2H, m), 7.58 (2H, m), 7.68 (1H, m ), 7.78 (1H, m), 8.05 (2H, m), 8.22 (1H, m), 8.40 (1H, m), 8.45 (2H, m), 8.59 (1H, m). Example 3 The following compounds were obtained following the method analogous to Example 1 or 2. (1) 2- (3-pyridylmethyl) -4- [3- [5-[(E) -2- (4-pyridyl) vinyl] pyridin-3-yl] phenyl] -3-oxo-3 , 4-dihydropyrido [2,3-b] pyrazine. mp: 253-257 ° C. NMR (CDCl 3, δ): 4.32 (2H, s), 7.13 (1H, d, J = 16 Hz), 7.2-7.4 (6H, m), 7.53 (1H, m), 7.7-7.85 (3H, m) , 8.03 (1H, t, J = 2Hz), 8.21 (1H, dd, J = 2, 8Hz), 8.43 (1H, dd, J = 2, 5Hz), 8.51 (1H, dd, J = 2, 5Hz) , 8.61 (2H, d, J = 5 Hz), 8.73 (2H, t, J = 2 Hz), 8.80 (1H, d, J = 2 Hz). (2) 4- [3- [3-[(E) -3- (2-pyridyl) acryloylamino] phenyl] phenyl] -2- (3-pyridylmethyl) -3-oxo-3, 4-dihydropyrido [2,3-b] pyrazine. mp: 195-211 ° C. NMR (DMSO-d 6, δ): 4.27 (2H, s), 7.3-7.5 (8H, m), 7.6-7.8 (7H, m), 7.86 (1H, dd, J = 8, 8 Hz), 8.05 ( 1H, m), 8.21 (1H, m), 8.40 (1H, m), 8.46 (1H, m), 8.60 (1H, m), 8.63 (1H, m). (3) 4- [3- [3-[(E) -3- (6-acetamido-3-pyridyl) acryloylamino] phenyl] phenyl] -2- (3-pyridylmethyl)- 3-oxo-3,4-dihydropyrido [2,3-b] pyrazine. mp: 233-237 ° C. NMR (DMSO-d 6, δ): 2.11 (3H, s), 4.27 (2H, s), 6.80 (1H, d, J = 16 Hz), 7.40 (5H, m), 7.57 (1H, d, J = 16 Hz), 7.68 (3H, m), 7.78 (2H, m), 8.04 (2H, m), 8.19 (2H, m), 8.41 (1H, m), 8.45 (1H, m), 8.53 (1H, m ), 8.60 (1 H, m). (4) 2- (3-pyridylmethyl) -4- [3-[(E) -2- [5-[(E) -2-methoxycarbonylvinyl] pyridin-3-yl] vinyl] phenyl ] -3-oxo-3,4-dihydropyrido [2,3-b] pyrazine. mp: 196-199 ° C. NMR (CDCl 3, δ): 3.82 (3H, s), 4.31 (2H, s), 6.56 (1H, d, J = 16 Hz). 7.09 (1H, d, J = 16 Hz), 7.2-7.35 (4H, m), 7.45 (1H, s), 7.55-7.75 (3H, m), 7.82 (1H, dd, J = 2, 8 Hz), 7.90 (1H, d, J = 2Hz), 8.20 (1H, dd, J = 2, 8Hz), 8.44 (1H, m), 8.51 (1H, m), 8.61 (1H, s), 8.69 (1H, s) , 8.73 (1 H, s). (5) 2- (3-pyridylmethyl) -4- [3-[(E) -2- (1-oxido-3-pyridyl) vinyl] phenyl] -3-oxo-3,4-di Hydropyrido [2,3-b] pyrazine. NMR (CDCl 3, δ): 6.89 (1H, dd, J = 5, 8 Hz), 7.01 (1H, d, J = 16 Hz), 7.20 (1H, d, J = 16 Hz), 7.3-7.5 (4H, m ), 7.84 (1H, s), 8.19 (1H, d, J = 7 Hz), 8.5-8.6 (2H, m). (6) 2- (3-pyridylmethyl) -4- [3-[(E) -2- (1-oxido-4-pyridyl) vinyl] phenyl] -3-oxo-3,4-di Hydropyrido [2,3-b] pyrazine. NMR (CDCl 3, δ): 4.32 (2H, s), 6.98 (1H, d, J = 16 Hz), 7.15-7.35 (6H, m), 7.42 (1H, s), 7.55-7.7 (2H, m) , 7.82 (1H, d, J = 8 Hz), 8.1-8.25 (3H, m), 8.42 (1H, d, J = 5 Hz), 8.51 (1H, d, J = 5 Hz), 8.72 (1H, s). (7) 4- [3- [3-[(E) -3- (1-oxido-4-pyridyl) acryloylamino] phenyl] phenyl] -2- (3-pyridylmethyl) -3 Oxo-3,4-dihydropyrido [2,3-b] pyrazine. mp: 190-195 ° C. NMR (DMSO-d 6, δ): 4.26 (2H, s), 6.87 (1H, d, J = 16 Hz), 7.3-7.5 (5H, m), 7.55 (1H, d, J = 16 Hz), 7.6- 7.8 (7H, m), 8.01 (1H, s), 8.22 (3H, m), 8.40 (1H, d, J = 5 Hz), 8.47 (1H, d, J = 5 Hz), 8.60 (1H, s). (8) 4- [3- (2-methylbenzothiazol-5-yl) phenyl] -2- (3-pyridylmethyl) -3-oxo-3,4-dihydropyrido [2,3- b] pyrazine. mp: 198-200 ° C. NMR (DMSO-d 6 , δ): 2.80 (3H, s), 4.28 (2H, s), 7.37 (3H, m), 7.65-7.72 (1H, m), 7.80 (2H, m), 7.91 (1H , m), 8.11 (1H, d, J = 8 Hz), 8.21 (2H, m), 8.42 (1H, d, J = 5 Hz), 8.46 (1H, d, J = 5 Hz), 8.60 (1H, s) . (9) 4- [3- (2-methylbenzothiazol-6-yl) phenyl] -2- (3-pyridylmethyl) -3-oxo-3,4-dihydropyrido [2,3- b] pyrazine. mp: 241-243 ° C. NMR (DMSO-d 6 , δ): 2.80 (3H, s), 4.27 (2H, s), 7.40 (3H, m), 7.65 (1H, dd, J = 8, 8 Hz), 7.80 (3H, m) , 7.90 (1H, m), 7.97 (1H, d, J = 8 Hz), 8.22 (1H, dd, J = 8, 2 Hz), 8.38 (1H, d, J = 2 Hz), 8.40 (1H, m), 8.45 (1 H, m), 8.60 (1 H, d, J = 2 Hz). (10) 4- [3-[(E) -2- (5-methoxycarbonylpyridin-3-yl) vinyl] phenyl] -2- (3-pyridylmethyl) -3-oxo-3,4 -Dihydropyrido [2,3-b] pyrazine. mp: 171-173 ° C. NMR (DMSO-d 6 , δ): 3.90 (3H, s), 4.26 (2H, s), 7.32 (1H, m), 7.40 (3H, m), 7.60 (2H, m), 7.68 (1H, s ), 7.80 (2H, m), 8.22 (1H, d, J = 8 Hz), 8.42 (1H, m), 8.48 (2H, m), 8.60 (1H, s), 8.95 (1H, m), 9.00 ( 1H, m). (11) 2- (3-pyridylmethyl) -4- [3- (6-methoxy-5-bromo-2-naphthyl) phenyl] -3-oxo-3,4-dihydropyrido [ 2,3-b] pyrazine. mp: 211-214 ° C. NMR (CDCl 3 , δ): 4.04 (3H, s), 4.34 (2H, s), 7.24-7.35 (4H, m), 7.60 (1H, m), 7.70 (1H, dd, J = 8, 8 Hz) , 7.80-7.90 (4H, m), 8.00 (1H, m), 8.19 (1H, dd, J = 8, 2 Hz), 8.25 (1H, d, J = 8 Hz), 8.45 (1H, m), 8.50 ( 1 H, m), 8.74 (1 H, m). Example 4 2- (3-pyridylmethyl) -4- [3-[(E) -2- (3-pyridyl) vinyl] phenyl] -3-oxo-3,4-dihydro in dichloromethane (20 mL) To a solution of pyrido [2,3-b] pyrazine (374 mg) was added m-chloroperbenzoic acid (232 mg). The mixture was stirred for 1 h in an ice bath, then poured into aqueous sodium bicarbonate and extracted with chloroform. The organic solution was washed with aqueous sodium bicarbonate and brine, dried over magnesium sulfate and then concentrated. The residue was chromatographed on a silica gel column (chloroform-methanol, 9: 1) to give 2-[(1-oxido-3-pyridyl) methyl] -4- [3-[(E) -2- (1- Oxydo-3-pyridyl) vinyl] phenyl] -3-oxo-3,4-dihydropyrido [2,3-b] pyrazine (43 mg) was obtained. NMR (CDCl 3 , δ): 4.29 (2H, s), 6.92 (1H, d, J = 16 Hz), 7.15-7.45 (8H, m), 7.6-7.7 (2H, m), 8.13 (3H, m) , 8.21 (1H, d, J = 8 Hz), 8.3-8.4 (2H, m), 8.48 (1H, dd, J = 2, 5 Hz). Example 5 4- [3-[(E) -2- (3,5-dichlorophenyl) vinyl] phenyl] -2- (3-pyridylmethyl) -3-oxo-3,4- in dichloromethane (10 mL) To a solution of dihydropyrido [2,3-b] pyrazine (255 mg) was added m-chloroperbenzoic acid (181 mg). The mixture was stirred at rt for 1 h, then poured into aqueous sodium bicarbonate and extracted with chloroform. The organic solution was washed with aqueous sodium bicarbonate and brine, dried over magnesium sulfate and then concentrated. The resulting solid was washed with diisopropyl ether to give 4- [3-[(E) -2- (3,5-dichlorophenyl) vinyl] phenyl] -2-[(1-oxido-3-pyridyl) Methyl] -3-oxo-3,4-dihydropyrido [2,3-b] pyrazine (167 mg) was obtained. NMR (CDCl 3 , δ): 4.28 (2H, s), 6.97 (1H, d, J = 16 Hz), 7.1-7.45 (9H, m), 7.55-7.7 (2H, m), 8.12 (1H, d, J = 5 Hz), 8.20 (1H, d, J = 8 Hz), 8.36 (1H, s), 8.47 (1H, m). Example 6 The following compounds were obtained following methods similar to Examples 4 or 5. (1) 4- [3- (3-acetamidophenyl) phenyl] -2-[(1-oxidodo-3-pyridyl) methyl] -3-oxo-3,4-dihydropyrido [2 , 3-b] pyrazine. NMR (CDCl 3 , δ): 2.16 (3H, s), 4.25 (2H, s), 7.24 (2H, m), 7.34 (3H, m), 7.43 (2H, m), 7.52 (1H, m), 7.64 (1H, dd, J = 8, 8 Hz), 7.69 (1H, m), 7.73 (2H, m), 8.12 (1H, m), 8.18 (1H, d, J = 8 Hz), 8.38 (1H, s ), 8.45 (1H, doublet, J = 5 Hz). (2) 2-[(1-oxidodo-3-pyridyl) methyl] -4- [3-[(E) -2- (1-oxido-4-pyridyl) vinyl] phenyl] -3- Oxo-3,4-dihydropyrido [2,3-b] pyrazine. mp: 168-180 ° C. NMR (CDCl 3 , δ): 4.28 (2H, s), 6.99 (1H, d, J = 16 Hz), 7.15-7.45 (8H, m), 7.55-7.7 (2H, m), 8.1-8.25 (4H, m), 8.37 (1 H, s), 8.47 (1 H, m). Example 7 4- [3-[(E) -2- (6-acetamido-3-pyridyl) vinyl] phenyl] -2- (3-pyridylmethyl) -3-oxo- in 4N hydrochloric acid (30 mL) A solution of 3,4-dihydropyrido [2,3-b] pyrazine (1.56 g) was refluxed for 1 hour. The cooling reaction was diluted with water, the precipitated material collected, washed with water and dried to give 4- [3-[(E) -2- (6-amino-3-pyridyl) vinyl] phenyl] -2- (3- Pyridylmethyl) -3-oxo-3,4-dihydropyrido [2,3-b] pyrazinedihydrochloride (1.65 g) was obtained. mp: 215-222 ° C. NMR (DMSO-d 6 , δ): 4.48 (2H, s), 7.08 (1H, d, J = 8 Hz), 7.20 (1H, d, J = 16 Hz), 7.28 (2H, m), 7.40 (1H, dd, J = 8, 5 Hz), 7.52 (1H, s), 7.58 (1H, dd, J = 8, 8 Hz), 7.66 (1H, d, J = 8 Hz), 8.02 (1H, dd, J = 8, 5 Hz), 8.06 (1H, s), 8.18 (1H, d, J = 8 Hz), 8.33 (3H, m), 8.42 (1H, d, J = 5 Hz), 8.52 (1H, d, J = 8 Hz), 8.83 (1 H, d, J = 5 Hz), 8.92 (1 H, s). Example 8 Following the same method as in Example 7, the following compound was obtained. 4- [3- (3-aminophenyl) phenyl] -2-[(1-oxidodo-3-pyridyl) methyl] -3-oxo-3,4-dihydropyrido [2,3-b] Pyrazine. NMR (CDCl 3 , δ): 4.27 (2H, s), 6.67 (1H, dd, J = 8, 2 Hz), 6.91 (1H, m), 6.99 (1H, d, J = 8 Hz), 7.22 (3H, m), 7.31 (1H, dd, J = 8, 5 Hz), 7.43 (2H, m), 7.63 (1H, dd, J = 8, 8 Hz), 7.72 (1H, m), 8.13 (1H, m), 8.18 (1H, d, J = 8 Hz), 8.36 (1H, s), 8.45 (1H, d, J = 5 Hz). Example 9 4- [3-[(E) -2- (6-amino-3-pyridyl) vinyl] phenyl] -2- (3-pyridylmethyl) -3-oxo-3,4-dihydropyrido [ To a suspension of 2,3-b] pyrazinedihydrochloride (0.3 g) was added triethylamine (0.17 g) and anhydrous bis (trifluoroacetyl) (0.14 g). The mixture was stirred for 2 hours, the precipitated colorless crystals were collected, washed with methylene chloride and dried to afford 4- [3-[(E) -2- (6-trifluoroacetylamino-3-pyridyl) vinyl] Phenyl] -2- (3-pyridylmethyl) -3-oxo-3,4-dihydropyrido [2,3-b] pyrazine (0.28 g) was obtained. mp: 155-163 ° C. NMR (DMSO-d 6 , δ): 4.40 (2H, s), 7.02 (1H, d, J = 8 Hz), 7.18 (1H, d, J = 16 Hz), 7.28 (2H, m), 7.41 (1H, dd, J = 8, 5 Hz), 7.53 (1H, s), 7.60 (1H, s), 7.68 (1H, m), 7.79 (1H, dd, J = 8, 5 Hz), 8.05 (1H, s), 8.20-8.35 (4H, m), 8.42 (1H, m), 8.71 (1H, m), 8.80 (1H, s). Example 10 4- (3-aminophenyl) -2- (3-pyridylmethyl) -3-oxo-3,4-dihydropyrido [2,3-b] pyrazine in 1,4-dioxane (10 mL) To the solution of (300 mg) was added 5-bromo-3-pyridylcarbonyl chloride hydrochloride (304 mg). The mixture was stirred at rt for 15 min, then poured into aqueous sodium bicarbonate and extracted with ethyl acetate. The organic solution was washed with aqueous sodium bicarbonate and brine, dried over magnesium sulfate and then concentrated. The residue was crystallized from methanol to give 4- [3-[(5-bromo-3-pyridyl) carbonylamino] phenyl] -2- (3-pyridylmethyl) -3-oxo-3,4-di Hydropyrido [2,3-b] pyrazine (256 mg) was obtained. mp: 223-226 ° C. NMR (CDCl 3 , δ): 4.32 (2H, s), 6.78 (1H, d, J = 8 Hz), 7.12 (1H, dd, J = 5, 8 Hz), 7.3-7.45 (2H, m), 7.56 ( 1H, s), 7.7-7.8 (2H, m), 8.2-8.3 (2H, m), 8.32 (1H, m), 8.43 (1H, m), 8.65 (1H, s), 8.74 (1H, d, J = 2 Hz), 8.88 (1 H, s), 8.91 (1 H, s). Example 11 The following compounds were obtained following the method analogous to Example 10. (1) 4- [3- [3-[(E) -3- (4-chlorophenyl) acryloylamino] phenyl] phenyl] -2- (3-pyridylmethyl) -3-oxo-3, 4-dihydropyrido [2,3-b] pyrazine. mp: 187-193 ° C. NMR (CDCl 3 , δ): 4.33 (2H, s), 6.50 (1H, d, J = 16 Hz), 7.2-7.45 (8H, m), 7.47 (1H, m), 7.52 (1H, m), 7.62 (2H, m), 7.72 (2H, m), 7.84 (3H, m), 8.20 (1H, m), 8.42 (1H, m), 8.50 (1H, m), 8.75 (1H, s). (2) 4- [3- [3-[(E) -3- (3-chlorophenyl) propenoylamino] phenyl] phenyl] -2- (3-pyridylmethyl) -3-oxo-3, 4-dihydropyrido [2,3-b] pyrazine. mp: 214-217 ° C. NMR (CDCl 3 , δ): 4.33 (2H, s), 6.52 (1H, d, J = 16 Hz), 7.2-7.4 (8H, m), 7.50 (2H, m), 7.54 (1H, m), 7.65 (3H, m), 7.74 (1H, m), 7.85 (2H, m), 8.20 (1H, m), 8.43 (1H, m), 8.51 (1H, m), 8.75 (1H, m). (3) 4- [3- [3-[(E) -3- (2-chlorophenyl) propenoylamino] phenyl] phenyl] -2- (3-pyridylmethyl) -3-oxo-3, 4-dihydropyrido [2,3-b] pyrazine. mp: 225-230 ° C. NMR (DMSO-d 6 , δ): 4.27 (2H, s), 6.89 (1H, d, J = 16 Hz), 7.4 (8H, m), 7.55 (1H, m), 7.67 (3H, m), 7.79 (3H, m), 7.88 (1H, d, J = 16 Hz), 8.07 (1H, m), 8.20 (1H, m), 8.41 (1H, m), 8.46 (1H, m), 8.60 (1H, m ). (4) 4- [3- [3-[(E) -3- (3-pyridyl) acryloylamino] phenyl] phenyl] -2- (3-pyridylmethyl) -3-oxo-3, 4-dihydropyrido [2,3-b] pyrazine. mp: 185-191 ° C. NMR (DMSO-d 6 , δ): 4.27 (2H, s), 7.03 (1H, d, J = 16 Hz), 7.40 (5H, m), 7.57 (3H, m), 7.75 (5H, m), 8.01 (1H, s), 8.21 (1H, m), 8.41 (1H, m), 8.47 (1H, m), 8.62 (3H, m). (5) 4- [3- [3-[(E) -3- (4-pyridyl) acryloylamino] phenyl] phenyl] -2-[(1-oxido-3-pyridyl) methyl] -3-oxo-3,4-dihydropyrido [2,3-b] pyrazine. NMR (CDCl 3 , δ): 4.28 (2H, s), 7.05 (1H, d, J = 16 Hz), 7.2-7.5 (9H, m), 7.62 (2H, m), 7.75 (2H, m), 7.95 (1H, m), 8.12 (1H, m), 8.19 (1H, m), 8.43 (2H, m), 8.60 (2H, m), 9.25 (1H, m). MASS (m / Z): 553 (M + l). Example 12 Pivaloyl chloride (0.33) in methylene chloride (5 mL) in a stirred suspension of 2- (3-pyridyl) thiazole-4-carboxylic acid (0.56 g) and triethylamine (0.55 g) in methylene chloride (25 mL) g) was added and the mixture was stirred for 2 hours. When the reaction mixture is clear, 4- [3- (3-aminophenyl) phenyl] -2- (3-pyridylmethyl) -3-oxo-3,4-dihydropyrido [2,3-b] pyrazine ( 1.0 g) was added and the mixture was stirred at reflux for 2 h. The reaction mixture was washed with sodium bicarbonate solution and water, dried over magnesium sulfate and then concentrated. The crude residue was chromatographed on silica gel (70 g, chloroform-methanol 100: 1 as eluent) to 4- [3- [3- [2- (3-pyridyl) thiazol-4-ylcarbonylamino] Phenyl] phenyl] -2- (3-pyridylmethyl) -3-oxo-3,4-dihydropyrido [2,3-b] pyrazine was obtained as colorless crystals (0.48 g). mp: 199-200 ° C. NMR (DMSO-d 6 , δ): 4.28 (2H, s), 7.38 (3H, m), 7.50 (2H, m), 7.60 (1H, dd, J = 8, 5 Hz), 7.70 (2H, m) , 7.80 (1H, m), 7.85 (1H, m), 7.95 (1H, m), 8.20 (2H, m), 8.41 (1H, m), 8.48 (1H, m), 8.50 (1H, m), 8.58 (2H, m), 8.73 (1H, m), 9.40 (1H, s). Example 13 2- (bromomethyl) -4- [3- [2- (6-methoxy-5-bromo) naphthyl] phenyl] -3-oxo-3 in N, N-dimethylformamide (40 mL) A mixture of, 4-dihydropyrido [2,3-b] pyrazine (4 g) and 1-acetylimidazole was stirred at 70 ° C. for 5 hours. To the mixture was added saturated sodium carbonate (40 mL) and chloroform (40 mL). The mixture was stirred for 30 minutes. The mixture was extracted with chloroform (2 x 40 mL). The organic layer was evaporated in vacuo. The crude product was purified by chromatography to give 2- (1-imidazolylmethyl) -4- [3-[(6-methoxy-5-bromo) -2-naphthyl] phenyl] -3-oxo- 3,4-dihydropyrido [2,3-b] pyrazine (1.7 g) was obtained. mp: 141-145 ° C. NMR (CDCl 3 , δ): 4.03 (3H, s), 5.43 (2H, s), 7.12 (1H, m), 7.17 (1H, m), 7.30 (2H, m), 7.35 (1H, dd, J = 8, 5 Hz), 7.61 (1H, m), 7.70 (1H, d, J = 8 Hz), 7.75 (1H, m), 7.85 (3H, m), 8.01 (1H, s), 8.21 (1H, d , J = 8 Hz), 8.28 (1H, d, J = 8 Hz), 8.50 (1H, m). MASS (m / z): 538 (M + 1), 540.
权利要求:
Claims (9) [1" claim-type="Currently amended] A compound of formula (I) and a pharmaceutically acceptable salt thereof: In the above formula, R 1 is pyridyl (lower) alkyl, N-oxidodopyridyl (lower) alkyl or imidazolyl (lower) alkyl, R 2 is aminophenyl, [protected amino] phenyl, [[[halophenyl] (lower) alkenoyl] amino] phenyl, [[pyridyl (lower) alkenoyl] amino] phenyl, [[[N-oxaido Pyridyl] (lower) alkenoyl] amino] phenyl, [[[protected aminopyridyl] (lower) alkenoyl] amino] phenyl, [thiazolylcarbonylamino] phenyl which may have pyridyl, lower alkoxy and Naphthyl with halogen, [dihalophenyl] (lower) alkenyl, [N-oxidodopyridyl] (lower) alkenyl, [aminopyridyl] (lower) alkenyl, [protected aminopyridyl] ( Lower) alkenyl, [carboxypyridyl] (lower) alkenyl, [protected carboxypyridyl] (lower) alkenyl, [[pyridyl (lower) alkenyl] pyridyl] (lower) alkenyl, [[ Carboxy (lower) alkenyl] pyridyl] (lower) alkenyl, [[protected carboxy (lower) alkenyl] pyridyl] (lower) alkenyl, [pyridyl (lower) alkenyl] pyridyl, lower alkyl Benzothiazolyl or [halopyridylcarbonyl] amino, Provided that when R 2 is [[4-pyridyl (lower) alkenoyl] amino] phenyl, aminophenyl, [lower alkanoylamino] phenyl or [dihalophenyl] (lower) alkenyl, then R 1 is N- Oxidopyridyl (lower) alkyl or imidazolyl (lower) alkyl. [2" claim-type="Currently amended] The method of claim 1, R 1 is pyridyl (lower) alkyl, N-oxidodopyridyl (lower) alkyl or imidazolyl (lower) alkyl, R 2 is aminophenyl, [lower alkanoylamino] phenyl, [[[halophenyl] (lower) alkenoyl] amino] phenyl, [[pyridyl (lower) alkenoyl] amino] phenyl, [[[N-oxa Idopyridyl] (lower) alkenoyl] amino] phenyl, [[[acylaminopyridyl] (lower) alkenoyl] amino] phenyl (more preferably [[[[lower alkanoylamino] pyridyl] (lower) ) Alkenoyl] amino] phenyl), [[pyridylthiazolyl] carbonylamino] phenyl, naphthyl with lower alkoxy and halogen, [dihalophenyl] (lower) alkenyl, [N-oxidopyridyl] (Lower) alkenyl, [aminopyridyl] (lower) alkenyl, [[acylamino] pyridyl] (lower) alkenyl (more preferably [[lower alkanoylamino] pyridyl] (lower) alkenyl Or [[mono (or di or tri) halo (lower) alkanoylamino] pyridyl] (lower) alkenyl; most preferably [[lower alkanoylamino] pyridyl] (lower) alkenyl or [[tri Halo (lower) alkanoylamino] Pyridyl] (lower) alkenyl), [carboxypyridyl] (lower) alkenyl, [esterified carboxypyridyl] (lower) alkenyl (more preferably [lower alkoxycarbonylpyridyl] (lower) Alkenyl), [[pyridyl (lower) alkenyl] pyridyl] (lower) alkenyl, [[carboxy (lower) alkenyl] pyridyl] (lower) alkenyl, [[esterified carboxy (lower) Alkenyl] pyridyl] (lower) alkenyl (more preferably [[lower alkoxycarbonyl (lower) alkenyl] pyridyl] (lower) alkenyl), [pyridyl (lower) alkenyl] pyridyl, Lower alkylbenzothiazolyl or halopyridylcarbonylamino, Provided that when R 2 is [[4-pyridyl (lower) alkenoyl] amino] phenyl, aminophenyl, [lower alkanoylamino] phenyl or [dihalophenyl] (lower) alkenyl, then R 1 is N- A compound which is oxidopyridyl (lower) alkyl or imidazolyl (lower) alkyl. [3" claim-type="Currently amended] The method of claim 2, R 1 is pyridyl (lower) alkyl, R 2 is [[2-pyridyl (lower) alkenoyl] amino] phenyl, [[3-pyridyl (lower) alkenoyl] amino] phenyl, [[pyridylthiazolyl] carbonylamino] phenyl, [amino Pyridyl] (lower) alkenyl, [[lower alkanoylamino] pyridyl] (lower) alkenyl, [[trihalo (lower) alkanoylamino] pyridyl] (lower) alkenyl, [lower alkoxycarbo Nylpyridyl] (lower) alkenyl, [[pyridyl (lower) alkenyl] pyridyl] (lower) alkenyl or loweralkylbenzothiazolyl. [4" claim-type="Currently amended] The method of claim 2, R 1 is imidazolyl (lower) alkyl, R 2 is naphthyl having lower alkoxy and halogen. [5" claim-type="Currently amended] (1) reacting a compound of formula (II) or a salt thereof with a compound of formula (III) or a salt thereof to obtain a compound of formula (I) or a salt thereof, or (2) conducting an acylation reaction on the compound of formula (Ia), its reactive derivative in the amino group or its salt to obtain a compound of formula (Ib) or a salt thereof, or (3) deacylating the compound of formula (Ic) or a salt thereof to obtain a compound of formula (Id) or a salt thereof, or (4) A compound of formula (If) by reacting a compound of formula (Ie), a reactive derivative thereof or a salt thereof in an amino group with a compound of formula (IV), a reactive derivative thereof in a carboxy group or a salt thereof Or to obtain a salt thereof, (5) Compounds of formula (I) characterized in that the removal of N-protecting groups is carried out to the compounds of formula (VII) or salts thereof to yield compounds of formula (Ig) or salts thereof How to prepare its salts: In the above formula, R 1 and R 2 are each as defined in claim 1, R 2 a is [aminopyridyl] (lower) alkenyl, R 2 b is [acylaminopyridyl] (lower) alkenyl, R 2 c is [lower alkanoylamino] phenyl, [[[halophenyl] (lower) alkenoyl] amino] phenyl, [[pyridyl (lower) alkenoyl] amino] phenyl, [[[N-oxidodopyri Dill] (lower) alkenoyl] amino] phenyl, [[[protected aminopyridyl] (lower) alkenoyl] amino] phenyl, [thiazolylcarbonylamino] phenyl or acylaminopyrid, which may have pyridyl Dill] (lower) alkenyl, R 2 d is aminophenyl or [aminopyridyl] (lower) alkenyl, R 2 e is aminophenyl, R 3 is lower alkanoyl, [halophenyl] (lower) alkenoyl, pyridyl (lower) alkenoyl, [N-oxidodopyridyl] (lower) alkenoyl, [protected aminopyridyl] (lower) alkenes Thiazolylcarbonyl, which may have noyl or pyridyl, R 2 f is [lower alkanoylamino] phenyl, [[[halophenyl] (lower) alkenoyl] amino] phenyl, [[pyridyl (lower) alkenoyl] amino] phenyl, [[[N-oxidodopyri Dill] (lower) alkenoyl] amino] phenyl, [[[protected aminopyridyl] (lower) alkenoyl] amino] phenyl or [thiazolylcarbonylamino] phenyl, which may have pyridyl, R 4 is an N-protecting group, A is lower alkylene, Y - is a halide. [6" claim-type="Currently amended] A pharmaceutical composition containing as an active ingredient the compound of claim 1 or a pharmaceutically acceptable salt thereof as a mixture with a pharmaceutically acceptable carrier. [7" claim-type="Currently amended] Use of the compound of claim 1 or a pharmaceutically acceptable salt thereof as an inhibitor of phosphodiesterase IV (PDE IV) production and tumor necrosis factor (TNF) production. [8" claim-type="Currently amended] A method of preventing or treating a disease mediated by phosphodiesterase IV (PDE IV) and tumor necrosis factor (TNF), characterized in that the compound of claim 1 or a pharmaceutically acceptable salt thereof is administered to a human or animal. [9" claim-type="Currently amended] A method for preparing a pharmaceutical composition, characterized in that the compound of claim 1 or a pharmaceutically acceptable salt thereof is mixed with a pharmaceutically acceptable carrier.
类似技术:
公开号 | 公开日 | 专利标题 KR101564634B1|2015-10-30|Condensed aminodihydrothiazine derivative US8178553B2|2012-05-15|Compounds for the treatment of inflammatory disorders JP4107687B2|2008-06-25|Substituted N-[| phenyl] propylamide US7642275B2|2010-01-05|Histone deacetylase inhibitors EP1812439B2|2017-12-06|Kinase inhibitors EP3080120B1|2019-06-19|Fused imidazole and pyrazole derivatives as modulators of tnf activity US7482370B2|2009-01-27|Compounds for the treatment of inflammatory disorders CA2705452C|2016-05-31|Mapk/erk kinase inhibitors EP2114869B1|2014-07-23|Rho kinase inhibitors US7572914B2|2009-08-11|Kinase inhibitors JP5640006B2|2014-12-10|Condensed heterocyclic inhibitors of histone deacetylases and / or cyclin-dependent kinases US4421912A|1983-12-20|Cephalosporin derivatives JP4439265B2|2010-03-24|Compounds for treating inflammatory disorders AU2001261167B2|2006-10-05|Beta-carboline derivatives useful as inhibitors of phosphodiesterase US6232320B1|2001-05-15|Cell adhesion-inhibiting antiinflammatory compounds US6348474B1|2002-02-19|Sulfonamide compounds and medicinal use thereof US6908938B2|2005-06-21|Heterocyclic aromatic compounds useful as growth hormone secretagogues JP5092402B2|2012-12-05|Pyrazolopyridine derivative KR101023035B1|2011-03-24|Cephem compounds DE3404615C2|1989-06-15| KR100315759B1|2002-04-06|Guanidine derivatives as Na + / H + exchange inhibitors in cells ES2430966T3|2013-11-22|MAPK / ERK kinase inhibitors JP2600644B2|1997-04-16|Thiazolyl benzofuran derivative US7232832B2|2007-06-19|Antibacterial agents US6765005B2|2004-07-20|Fab I inhibitors
同族专利:
公开号 | 公开日 EP0874845B1|2002-03-06| IL124673A|2002-07-25| MX9805129A|1998-10-31| CN1066732C|2001-06-06| EA001324B1|2001-02-26| ES2170286T3|2002-08-01| DE69619702T2|2002-08-14| GB9526558D0|1996-02-28| CN1205702A|1999-01-20| AU1111297A|1997-07-28| DK0874845T3|2002-07-01| EP0874845A1|1998-11-04| HU9901038A2|1999-07-28| WO1997024355A1|1997-07-10| PT874845E|2002-08-30| AU720301B2|2000-05-25| AT214067T|2002-03-15| DK874845T3| EA199800599A1|1998-12-24| US6117875A|2000-09-12| IL124673D0|1998-12-06| JP2000502699A|2000-03-07| CA2241690A1|1997-07-10| DE69619702D1|2002-04-11| HU9901038A3|2000-04-28|
引用文献:
公开号 | 申请日 | 公开日 | 申请人 | 专利标题
法律状态:
1995-12-27|Priority to GBGB9526558.3A 1995-12-27|Priority to GB9526558.3 1996-12-13|Application filed by 후지야마 아키라, 후지사와 야꾸힝 고교 가부시키가이샤 1996-12-13|Priority to PCT/JP1996/003666 1999-09-27|Publication of KR19990072053A
优先权:
[返回顶部]
申请号 | 申请日 | 专利标题 GBGB9526558.3A|GB9526558D0|1995-12-27|1995-12-27|Heterobicyclic derivatives| GB9526558.3|1995-12-27| PCT/JP1996/003666|WO1997024355A1|1995-12-27|1996-12-13|Pyridopyrazine derivatives| 相关专利
Sulfonates, polymers, resist compositions and patterning process
Washing machine
Washing machine
Device for fixture finishing and tension adjusting of membrane
Structure for Equipping Band in a Plane Cathode Ray Tube
Process for preparation of 7 alpha-carboxyl 9, 11-epoxy steroids and intermediates useful therein an
国家/地区
|